Gene editing system targeting PTBP1 and use thereof

By using a gRNA gene editing system that targets PTBP1 RNA, PTBP1 expression is inhibited, and astrocytes are promoted to transdifferentiate into neurons. This solves the problem of neuronal loss in neurodegenerative diseases and achieves neuronal regeneration and functional improvement.

WO2024245152A1PCT designated stage expired Publication Date: 2024-12-05GUANGZHOU REFORGENE MEDICINE CO LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/095288
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-02-08
Filing Date
2024-05-24
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Current technologies lack effective treatments for neurodegenerative diseases such as amyotrophic lateral sclerosis, Alzheimer's disease, and Parkinson's disease, especially motor impairments and cognitive decline caused by the selective death of dopaminergic neurons.

Method used

We developed gRNAs and their gene editing systems that target polypyrimidine region-binding protein (PTBP1) RNA. By inhibiting PTBP1 expression, we promoted the directed transdifferentiation of astrocytes into neurons. We utilized gRNAs to form complexes with RNA-guided nucleases, which specifically bound to and cleaved PTBP1 RNA, thereby reducing its expression level.

Benefits of technology

This technology has enabled the promotion of neuronal regeneration and functional neural tissue growth in neurodegenerative diseases, improving motor function and cognitive abilities, and providing potential treatment options.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2024095288-FTAPPB-I100001
    Figure PCTCN2024095288-FTAPPB-I100001
  • Figure PCTCN2024095288-FTAPPB-I100002
    Figure PCTCN2024095288-FTAPPB-I100002
  • Figure PCTCN2024095288-FTAPPB-I100003
    Figure PCTCN2024095288-FTAPPB-I100003
Patent Text Reader

Abstract

Disclosed are a gene editing system targeting PTBP1 and the use thereof. The gene editing system comprises a gRNA targeting a target RNA and an RNA guided nuclease, the target RNA being human, mouse or monkey PTBP1 RNA, the gRNA comprising a targeting domain, and the targeting domain comprising a sequence shown as any one of SEQ ID No: 1-8 or SEQ ID No: 11-105, or a sequence having 80% identity with a sequence shown as any one of SEQ ID No: 1-8 or SEQ ID No: 11-105. The gene editing system can be used for diagnosing, treating or preventing diseases or disorders related to target RNAs.
Need to check novelty before this filing date? Find Prior Art

Description

Gene editing system targeting PTBP1 and its application

[0001] This application claims priority to:

[0002] CN2023106057479, application date: May 26, 2023;

[0003] CN2024101778199, application date: February 8, 2024. Technical Field

[0004] This disclosure belongs to the field of biotechnology, and specifically relates to gene editing systems and their applications. Background Art

[0005] Neurodegenerative diseases are characterized by the progressive and irreversible loss of neurons from specific brain regions. The pattern of neuronal loss is selective, primarily affecting subcortical regions (the nuclei basalis) and the cerebral cortex, leading to abnormalities in voluntary motor control, memory loss, and cognitive decline. This ultimately leads to the development of amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, and Huntington's disease. Currently, there are few effective treatment options for these neurodegenerative diseases, and there remains an urgent clinical need for corresponding therapeutic drugs.

[0006] Parkinson's disease (PD) is a common movement disorder. The primary pathological feature of PD is the selective and progressive death of dopaminergic neurons in the substantia nigra of the midbrain and the degeneration of fibers in the nigrostriatal pathway. Currently, clinical treatment primarily relies on levodopa (L-3,4-dihydroxyphenylalanine, L-DOPA) replacement therapy.

[0007] A promising direction of current research is to use regenerative technologies to regrow healthy and functional neural tissue in damaged areas. Various approaches currently under investigation to promote neural regeneration include stem cell-based therapies, scaffolds made of hydrogels, electrospun fibers and conductive materials, and the use of soluble or non-diffusible growth factors.

[0008] Polypyrimidine tract binding protein (PTBP1) is a key mRNA regulatory factor. It binds to RNA through four distinct binding regions, altering its structure and influencing mRNA splicing, translation, stability, and localization. PTBP1 plays a crucial role in physiological processes such as neuronal growth and differentiation, T cell activation, spermatogenesis, embryonic development, and erythrocyte development.

[0009] By inhibiting the expression of PTBP1, it is possible to achieve the directed transdifferentiation of other cells such as astrocytes into neurons, which can address the neuronal loss in neurodegenerative diseases and is a promising neural regeneration technology.

[0010] Gene-editing therapies for human diseases are currently under extensive development.

[0011] Summary of the Invention

[0012] The purpose of this disclosure is to provide gRNA targeting PTBP1 RNA and its gene editing system and application.

[0013] In a first aspect, the present disclosure protects a gRNA (guide RNA).

[0014] The gRNA claimed in the present disclosure is any one of the following 1)-3):

[0015] 1) the gRNA comprises a targeting domain, wherein the targeting domain comprises a sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 98% or 100% identical to the sequence shown in SEQ ID No: 122;

[0016] 2) the gRNA comprises a targeting domain, wherein the targeting domain comprises a sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 98% or 100% identical to the sequence shown in positions 638-685 of SEQ ID No: 121;

[0017] 3) The gRNA includes a targeting domain, which comprises a sequence as shown in any one of SEQ ID No: 1 to SEQ ID No: 8 or SEQ ID No: 11 to SEQ ID No: 60, or a sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 98% or 100% identity with the sequence shown in any one of SEQ ID No: 1 to SEQ ID No: 8 or SEQ ID No: 11 to SEQ ID No: 60.

[0018] In some embodiments of the present disclosure, the targeting domain is reverse complementary (fully complementary or partially complementary) to the PTBP1 RNA sequence.

[0019] In some embodiments of the present disclosure, the gRNA includes a targeting domain, which comprises a sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 98% or 100% identical to the sequence shown in SEQ ID No: 122; further, the targeting domain consists of a sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 98% or 100% identical to the sequence shown in SEQ ID No: 122.

[0020] In some embodiments of the present disclosure, the gRNA includes a targeting domain, which comprises a sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 98% or 100% identical to the sequence shown in SEQ ID No: 121, positions 638-685; further, the targeting domain consists of a sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 98% or 100% identical to the sequence shown in SEQ ID No: 121, positions 638-685.

[0021] In some embodiments of the present disclosure, the gRNA includes a targeting domain, which comprises a sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 98% or 100% identical to the sequence shown in any one of SEQ ID No: 1 to SEQ ID No: 8, SEQ ID No: 11 to SEQ ID No: 60; further, the targeting domain consists of a sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 98% or 100% identical to the sequence shown in any one of SEQ ID No: 1 to SEQ ID No: 8 or SEQ ID No: 11 to SEQ ID No: 60.

[0022] In some embodiments of the present disclosure, the targeting domain of the gRNA in 1) comprises the sequence shown in SEQ ID No: 122, positions 627-3697, or a sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 98%, or 100% identity thereto; further, the targeting domain of the gRNA comprises the sequence shown in any one of SEQ ID No: 85 to SEQ ID No: 105, or a sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 98%, or 100% identity thereto; further, the targeting domain of the gRNA is selected from SEQ ID No: 85 to SEQ ID No: Any sequence shown in No:105.

[0023] In some embodiments of the present disclosure, the targeting domain of the gRNA in 2) comprises a sequence shown in any one of SEQ ID No: 61 to SEQ ID No: 84, or a sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 98% or 100% identity with a sequence shown in any one of SEQ ID No: 61 to SEQ ID No: 84; further, the targeting domain of the gRNA is selected from the sequence shown in any one of SEQ ID No: 61 to SEQ ID No: 84.

[0024] In some embodiments of the present disclosure, the targeting domain of the gRNA in 3) comprises a sequence as shown in any one of SEQ ID No: 6, SEQ ID No: 16, SEQ ID No: 36, SEQ ID No: 40, SEQ ID No: 41, and SEQ ID No: 42, or a sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 98% or 100% identity with any one of SEQ ID No: 6, SEQ ID No: 16, SEQ ID No: 36, SEQ ID No: 40, SEQ ID No: 41, and SEQ ID No: 42; further, the targeting domain of the gRNA is selected from the sequence shown in any one of SEQ ID No: 6, SEQ ID No: 16, SEQ ID No: 36, SEQ ID No: 40, SEQ ID No: 41, and SEQ ID No: 42.

[0025] In some embodiments of the present disclosure, the targeting domain of the gRNA comprises a sequence as shown in any one of SEQ ID No: 1 to SEQ ID No: 38, SEQ ID No: 40 to SEQ ID No: 51, SEQ ID No: 53 to SEQ ID No: 57, SEQ ID No: 59 to SEQ ID No: 88, SEQ ID No: 90, SEQ ID No: 91, SEQ ID No: 95 to SEQ ID No: 105, or a sequence as shown in any one of SEQ ID No: 1 to SEQ ID No: 38, SEQ ID No: 40 to SEQ ID No: 51, SEQ ID No: 53 to SEQ ID No: 57, SEQ ID No: 59 to SEQ ID No: 88, SEQ ID No: 90, SEQ ID No: 91, SEQ ID No: 95 to SEQ ID No: 105. Any of the sequences shown in No: 105 has a sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 98% or 100% identical.

[0026] In some embodiments of the present disclosure, the targeting domain of the gRNA is selected from the sequence shown in any one of SEQ ID No: 1 to SEQ ID No: 38, SEQ ID No: 40 to SEQ ID No: 51, SEQ ID No: 53 to SEQ ID No: 57, SEQ ID No: 59 to SEQ ID No: 88, SEQ ID No: 90, SEQ ID No: 91, and SEQ ID No: 95 to SEQ ID No: 105.

[0027] In some embodiments of the present disclosure, the targeting domain of the gRNA comprises the sequence shown in any one of SEQ ID No: 1 to SEQ ID No: 3, SEQ ID No: 6, SEQ ID No: 9 to SEQ ID No: 12, SEQ ID No: 16, SEQ ID No: 18 to SEQ ID No: 21, SEQ ID No: 23, SEQ ID No: 24, SEQ ID No: 28, SEQ ID No: 30, SEQ ID No: 34, SEQ ID No: 36, SEQ ID No: 40 to SEQ ID No: 42, SEQ ID No: 51, SEQ ID No: 55, SEQ ID No: 61 to SEQ ID No: 76, SEQ ID No: 80 to SEQ ID No: 82, SEQ ID No: 84, SEQ ID No: 98, and SEQ ID No: 104, or a sequence thereof. No.: 23, SEQ ID No: 24, SEQ ID No: 28, SEQ ID No: 30, SEQ ID No: 34, SEQ ID No: 36, SEQ ID No: 40 to SEQ ID No: 42, SEQ ID No: 51, SEQ ID No: 55, SEQ ID No: 61 to SEQ ID No: 76, SEQ ID No: 80 to SEQ ID No: 82, SEQ ID No: 84, SEQ ID No: 98, SEQ ID No: 104, a sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 98% or 100% identity.

[0028] In some embodiments of the present disclosure, the targeting domain of the gRNA is selected from the sequence shown in any one of SEQ ID No: 1 to SEQ ID No: 3, SEQ ID No: 6, SEQ ID No: 9 to SEQ ID No: 12, SEQ ID No: 16, SEQ ID No: 18 to SEQ ID No: 21, SEQ ID No: 23, SEQ ID No: 24, SEQ ID No: 28, SEQ ID No: 30, SEQ ID No: 34, SEQ ID No: 36, SEQ ID No: 40 to SEQ ID No: 42, SEQ ID No: 51, SEQ ID No: 55, SEQ ID No: 61 to SEQ ID No: 76, SEQ ID No: 80 to SEQ ID No: 82, SEQ ID No: 84, SEQ ID No: 98, and SEQ ID No: 104.

[0029] In some embodiments of the present disclosure, the targeting domain of the gRNA comprises a sequence as shown in any one of SEQ ID No: 61 to SEQ ID No: 76, SEQ ID No: 80 to SEQ ID No: 82, and SEQ ID No: 84, or a sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 98% or 100% identical to any one of SEQ ID No: 61 to SEQ ID No: 76, SEQ ID No: 80 to SEQ ID No: 82, and SEQ ID No: 84.

[0030] In some embodiments of the present disclosure, the targeting domain of the gRNA is selected from the sequence shown in any one of SEQ ID No: 61 to SEQ ID No: 76, SEQ ID No: 80 to SEQ ID No: 82, and SEQ ID No: 84.

[0031] In some embodiments of the present disclosure, the targeting domain of the gRNA comprises a sequence as shown in any one of SEQ ID No: 98, SEQ ID No: 104, or a sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 98% or 100% identity to the sequence shown in any one of SEQ ID No: 98, SEQ ID No: 104.

[0032] In some embodiments of the present disclosure, the targeting domain of the gRNA is selected from the sequence shown in any one of SEQ ID No: 98 and SEQ ID No: 104.

[0033] In some embodiments of the present disclosure, the gRNA includes a backbone domain (backbone sequence), which is capable of binding to or interacting with an RNA-guided nuclease. The gRNA forms a complex with the RNA-guided nuclease and guides the complex to bind specifically to the sequence of the target RNA and cut the target RNA to reduce the expression level of the target RNA in an animal or animal cell.

[0034] In some embodiments of the disclosure, the complex reduces the expression level of the target RNA in the animal or animal cell by at least 5%.

[0035] In some embodiments of the present disclosure, the number of off-target genes when the complex binds to and cleaves the target RNA is less than 40. The number of off-target genes can be determined by taking the intersection of the differentially expressed gene set determined by RNA sequencing and the off-target gene set predicted by the program.

[0036] In some embodiments of the present disclosure, the RNA-guided nuclease may be a Cas protein. The Cas protein may be a Cas9 protein, a Cas12 protein, or a Cas13 protein. The Cas13 protein may specifically be a Cas13a protein, a Cas13b protein, a Cas13c protein, or a Cas13d protein.

[0037] In some embodiments of the present disclosure, the amino acid sequence of the Cas13 protein comprises a sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to the sequence shown in SEQ ID No: 107.

[0038] In some embodiments of the present disclosure, the amino acid sequence of the Cas13 protein comprises a sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to the sequence shown in SEQ ID No: 107.

[0039] In some embodiments of the present disclosure, the amino acid sequence of the Cas13 protein comprises a sequence having at least 90% sequence identity with the sequence shown in SEQ ID No: 107.

[0040] In some embodiments of the present disclosure, the amino acid sequence of the Cas13 protein comprises a sequence having at least 95% sequence identity with the sequence shown in SEQ ID No: 107.

[0041] In some embodiments of the present disclosure, the amino acid sequence of the Cas13 protein has at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity with the sequence shown in SEQ ID No: 107.

[0042] In some embodiments of the present disclosure, the amino acid sequence of the Cas13 protein comprises the sequence shown in SEQ ID No: 107.

[0043] In some embodiments of the present disclosure, the amino acid sequence of the Cas13 protein is shown in SEQ ID No: 107.

[0044] In some embodiments of the present disclosure, the amino acid sequence of the Cas13 protein comprises a sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to the sequence shown in SEQ ID No: 107, and the Cas13 protein is a mutant in which nuclease activity is inactivated.

[0045] In some embodiments, the Cas13 protein comprises 1, 2, 3, 4, 5 or 6 mutations at positions corresponding to amino acid residues R210, H215, R750, H755, R785 and / or H790 of the reference protein (C13-2) shown in SEQ ID No: 107. In some embodiments, the Cas13 protein is mutated to A (alanine) at positions corresponding to amino acid residues R210, H215, R750, H755, R785 and / or H790 of the reference protein shown in SEQ ID No: 107.

[0046] In some embodiments, the Cas13 protein comprises mutations at positions corresponding to amino acid residues R210 and H215 of the reference protein set forth in SEQ ID No: 107. In some embodiments, the Cas13 protein comprises mutations at positions corresponding to amino acid residues R750 and H755 of the reference protein set forth in SEQ ID No: 107. In some embodiments, the Cas13 protein comprises mutations at positions corresponding to amino acid residues R785 and H790 of the reference protein set forth in SEQ ID No: 107.

[0047] In some embodiments, the Cas13 protein comprises mutations at positions corresponding to amino acid residues R210, H215, R750, and H755 of the reference protein shown in SEQ ID No: 107.

[0048] In some embodiments, the Cas13 protein comprises mutations at positions corresponding to amino acid residues R750, H755, R785, and H790 of the reference protein shown in SEQ ID No: 107.

[0049] In some embodiments, the Cas13 protein comprises mutations at positions corresponding to amino acid residues R210, H215, R785 and / or H790 of the reference protein shown in SEQ ID No: 107.

[0050] In some embodiments, the Cas13 protein comprises mutations at positions corresponding to amino acid residues R210, H215, R750, H755, R785, and H790 of the reference protein shown in SEQ ID No: 107.

[0051] In some embodiments, the corresponding positions of R210, R750, or R785 are mutated to A. In some embodiments, the corresponding positions of H215, H755, or H790 are mutated to A. In some embodiments, the corresponding positions of R210, H215, R750, H755, R785, and H790 are all mutated to A.

[0052] In some embodiments, the Cas13 protein is obtained by introducing mutations into the RxxxxH motif at positions 210-215, the RxxxxH motif at positions 750-755, and / or the RxxxxH motif at positions 785-790 of the sequence shown in SEQ ID No: 107.

[0053] In some embodiments, the Cas13 protein is obtained by introducing 1, 2, 3, 4, 5 or 6 mutations at positions R210, H215, R750, H755, R785 and / or H790 of the sequence shown in SEQ ID No: 107. In some embodiments, the Cas13 protein is obtained by mutating positions R210, H215, R750, H755, R785 and / or H790 of the sequence shown in SEQ ID No: 107 to A (alanine).

[0054] In some embodiments, the Cas13 protein is obtained by mutating R210, H215, R785, and H790 of the sequence shown in SEQ ID No: 107 to A. In some embodiments, the Cas13 protein is obtained by mutating R210, H215, R750, and H755 of the sequence shown in SEQ ID No: 107 to A. In some embodiments, the Cas13 protein is obtained by mutating R750, H755, R785, and H790 of the sequence shown in SEQ ID No: 107 to A. In some embodiments, the Cas13 protein is obtained by mutating R210, H215, R750, H755, R785, and H790 of the sequence shown in SEQ ID No: 107 to A.

[0055] In some embodiments, the Cas13 protein comprises any one or more mutations at positions corresponding to the following amino acid residues of the reference protein as compared to SEQ ID No: 107: R11, N34, R35, R47, R58, R63, R64, N68, N87, N265, N274, R276, R290, R294, N299, N303, R308, R314, R320, R328, N332, R341, N346, R358, N372, N383, N390, N394, R47+R290, R47+R314, R290+R314, R47+R290+R314, R308+N 68. N394+N68, N87+N68, R308+N265, N394+N265, N87+N265, R308+N68+N265, N87+N68+N265, T7, A16, S260, A263, M266, N274, F288, M 302, N303, L304, V305, I311, D313, H324, P326, H327, N332, N346, T353, T360, E365, A373, M380, S382, K395, Y396, D402, D411, S418. Furthermore, compared to the reference protein shown in SEQ ID No: 107, the Cas13 protein comprises a mutation at a position corresponding to the D313 amino acid residue of the reference protein shown in SEQ ID No: 107.

[0056] In some embodiments, compared to the reference protein shown in SEQ ID No: 107, the Cas13 protein comprises any one or more mutations shown below at the corresponding positions of the following amino acid residues of the reference protein shown in SEQ ID No: 107: R11A, N34A, R35A, R47A, R58A, R63A, R64A, N68A, N87A, N265A, N274A, R276A, R290A, R294A, N299A, N303A, R308A, R314A, R320A, R328A, N332A, R341A, N346A, R358A, N372A, N383A, N390A, N394A, R47A+R290A, R47A+R314A, R290A+R314A, R47A+R290A+R314A, R308A+N68A, N394A+N68A, N87A+N68A, R308A+N265A, N394A+N265A, N87A+N265A, R308 A+N68A+N265A, N87A+N68A+N265A, T7S, A16S, S260E, A263K, M266I, N274K, F288Y, M302F, N303S, L304I, V305K, I311M, D3 13E, H324Y, P326S, H327V, N332Y, N346D, T353L, T360S, E365D, A373E, M380K, S382R, K395G, Y396D, D402L, D411E and S418K. Furthermore, compared to the reference protein shown in SEQ ID No: 107, the Cas13 protein comprises the following mutation at the corresponding position of the following amino acid residue of the reference protein shown in SEQ ID No: 107: D313E.

[0057] In some embodiments, the Cas13 protein can be obtained by introducing any one or more mutations at the following positions of the sequence shown in SEQ ID No: 107: R11, N34, R35, R47, R58, R63, R64, N68, N87, N265, N274, R276, R290, R294, N299, N303, R308, R314, R320, R328, N332, R341, N346, R358, N372, N383, N390, N394, R47+R290, R47+R314, R290+R314, R47+R290+R314, R308+N68, N 394+N68, N87+N68, R308+N265, N394+N265, N87+N265, R308+N68+N265, N87+N68+N265, T7, A16, S260, A263, M266, N274, F288, M30 2. N303, L304, V305, I311, D313, H324, P326, H327, N332, N346, T353, T360, E365, A373, M380, S382, K395, Y396, D402, D411, S418. Furthermore, the Cas13 protein can be obtained by introducing a mutation at position D313 of the sequence shown in SEQ ID No: 107.

[0058] In some embodiments, the Cas13 protein can be represented by SEQ ID The sequence shown in No: 107 is obtained by introducing any one or more of the following mutations at the following positions: R11A, N34A, R35A, R47A, R58A, R63A, R64A, N68A, N87A, N265A, N274A, R276A, R290A, R294A, N299A, N303A, R308A, R314A, R320A, R328A, N332A, R341A, N346A, R358A, N372A, N383A, N390A, N394A, R47A+R290A, R47A+R314A, R290A+R314A, R47A+R290A+R314A, R308A+N68A, N 394A+N68A, N87A+N68A, R308A+N265A, N394A+N265A, N87A+N265A, R308A+N68 A+N265A, N87A+N68A+N265A, T7S, A16S, S260E, A263K, M266I, N274K, F288Y, M3 02F, N303S, L304I, V305K, I311M, D313E, H324Y, P326S, H327V, N332Y, N346D, T353L, T360S, E365D, A373E, M380K, S382R, K395G, Y396D, D402L, D411E, and S418K.

[0059] In some embodiments, the Cas13 protein is a D313E mutant of the sequence shown in SEQ ID No: 107.

[0060] In some embodiments, the C13-2 protein, similar proteins of the C13-2 protein, mutants of the C13-2 protein, and their functional fragments or fusion proteins can form a complex with the direct repeat sequence comprising the sequence shown in SEQ ID No: 109 described in the present disclosure, and then specifically target the target RNA described in the present disclosure under the guidance of the guide sequence.

[0061] In some embodiments of the present disclosure, the RNA-guided nuclease may further comprise one or more of a subcellular localization signal, a deaminase domain, a translation activation domain, a translation repression domain, an RNA methylation domain, an RNA demethylation domain, a nuclease domain, a splicing factor domain, a reporter tag, and an affinity tag. The subcellular localization signal may be a nuclear localization signal or a nuclear export signal.

[0062] In some embodiments of the present disclosure, the targeting domain sequence of the gRNA is 20-40 bp in length.

[0063] In some embodiments of the present disclosure, the gRNA hybridizes to the target RNA with a mismatch of no more than 6 nucleotides.

[0064] In some embodiments of the present disclosure, the gRNA may further comprise a direct repeat sequence. The gRNA may be located at the 3' end or the 5' end of the direct repeat sequence. Specifically, the direct repeat sequence comprises the sequence shown in SEQ ID No: 109.

[0065] In some embodiments of the present disclosure, the gRNA may further comprise an aptamer sequence. In some embodiments of the present disclosure, the aptamer sequence may be located in the loop of the stem-loop structure of the direct repeat sequence secondary structure of the gRNA.

[0066] In some embodiments of the present disclosure, the gRNA may further comprise modified nucleotides. The modification may be 2'-O-methyl, 2'-O-methyl-3'-phosphorothioate, or 2'-O-methyl-3'-thioPACE. The modified nucleotides may be deoxyribonucleotides or locked nucleic acids.

[0067] In some embodiments of the present disclosure, the target RNA may be located in the nucleus or cytoplasm of a eukaryotic cell.

[0068] In a second aspect, the present disclosure protects the nucleic acid sequence encoding the above-mentioned gRNA.

[0069] In some embodiments of the present disclosure, the nucleic acid sequence encoding the gRNA is a DNA sequence. In some embodiments of the present disclosure, the nucleic acid sequence encoding the gRNA is an RNA sequence.

[0070] In some embodiments of the present disclosure, the nucleic acid sequence is codon optimized. In some embodiments of the present disclosure, the nucleic acid sequence is codon optimized for expression in a eukaryotic cell environment. In some embodiments of the present disclosure, the nucleic acid sequence is codon optimized for expression in a mammalian cell environment. In some embodiments of the present disclosure, the nucleic acid sequence is codon optimized for expression in a human cell environment. Alternatively, the nucleic acid sequence is a DNA sequence.

[0071] In a third aspect, the present disclosure protects an expression cassette, a recombinant vector, a recombinant bacterium, a recombinant virus or a transgenic cell line containing the above-mentioned gRNA encoding nucleic acid sequence. Optionally, the nucleic acid sequence is a DNA sequence.

[0072] In some embodiments of the present disclosure, an expression cassette containing the aforementioned DNA sequence is provided. In some embodiments of the present disclosure, a recombinant vector containing the aforementioned DNA sequence is provided. In some embodiments of the present disclosure, a recombinant bacterium containing the aforementioned DNA sequence is provided. In some embodiments of the present disclosure, a recombinant virus containing the aforementioned DNA sequence is provided. In some embodiments of the present disclosure, a transgenic cell line containing the aforementioned DNA sequence is provided.

[0073] The recombinant vector may be a recombinant adeno-associated virus vector or a recombinant lentivirus vector, for example, AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8 or AAV9.

[0074] In some embodiments of the present disclosure, the guide RNA or gene editing system described herein is packaged in an AAV vector, for example, packaged into an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAV PHP.B, AAV PHP.B2, AAV PHP.B3, AAV PHP.A, AAV PHP.eB, AAV PHP.eS, AAV2.7m8, AAV8.7m8, AAV ShH10, AAVrh10, or AAVrh74 capsid.

[0075] In some embodiments of the present disclosure, the guide RNA or gene editing system described herein is packaged into an AAV2, AAV5, AAV6, AAV8, AAV9, or AAV PHP.eB capsid.

[0076] In some embodiments of the present disclosure, the AAV vector described herein is optionally selected from: AAV2 / 2, AAV2 / 3, AAV2 / 4, AAV2 / 5, AAV2 / 6, AAV2 / 7, AAV2 / 8, AAV2 / 9, AAV2 / 10, AAV2 / 11, AAV2 / 12, AAV2 / 13, AAV2 / PHP.B, AAV2 / PHP.B2, AAV2 / PHP.B3, AAV2 / PHP.A, AAV2 / PHP.eB, AAV2 / PHP.eS, AAV2 / 2.7m8, AAV2 / 8.7m8, AAV2 / ShH10, AAV2 / rh10 and AAV2 / rh74.

[0077] In some embodiments of the present disclosure, the AAV vector described herein is selected from: AAV2 / 2, AAV2 / 5, AAV2 / 6, AAV2 / 8, AAV2 / 9, AAV2 / PHP.eB.

[0078] In some embodiments of the present disclosure, the expression cassette, recombinant vector, recombinant bacteria, recombinant virus or transgenic cell line may further include a regulatory sequence for regulating the expression of the gRNA. In some embodiments of the present disclosure, the recombinant vector may further include a regulatory sequence for regulating the expression of the gRNA. Further, the regulatory sequence may be a promoter or an enhancer. Further, the promoter may be a neuronal tissue-specific promoter or a neuronal cell-specific promoter. In some embodiments of the present disclosure, the promoter is a U6 promoter, a GFAP promoter (astrocyte-specific), a SYN1 promoter (neuron-specific) or a NSE / RU5' promoter (mature neuron-specific).

[0079] Fourthly, the present disclosure protects a gene editing system.

[0080] The gene editing system claimed in this disclosure includes (a) and (b):

[0081] (a) the gRNA disclosed herein, a nucleotide sequence encoding the gRNA, or an expression cassette, recombinant vector, recombinant bacteria, recombinant virus, or transgenic cell line containing the nucleotide sequence encoding the gRNA;

[0082] (b) an RNA-guided nuclease, a nucleotide sequence encoding the RNA-guided nuclease, or an expression cassette, a recombinant vector, a recombinant bacterium, a recombinant virus, or a transgenic cell line containing a nucleotide sequence encoding the RNA-guided nuclease.

[0083] In some embodiments of the present disclosure, the gRNA is capable of forming a complex with the RNA-guided nuclease and directing sequence-specific binding of the complex to the target RNA.

[0084] In some embodiments of the present disclosure, the gene editing system comprises:

[0085] (a) the gRNA disclosed herein, or a nucleotide sequence encoding the gRNA; and

[0086] (b) an RNA-guided nuclease, or a nucleotide sequence encoding the RNA-guided nuclease;

[0087] The gRNA is capable of forming a complex with the RNA-guided nuclease and directing the complex to sequence-specific binding to the target RNA.

[0088] In some embodiments of the present disclosure, the gene editing system comprises:

[0089] (a) the gRNA disclosed herein, or an expression cassette, recombinant vector, recombinant bacteria, recombinant virus or transgenic cell line containing a nucleotide sequence encoding the gRNA; and

[0090] (b) an RNA-guided nuclease, or an expression cassette, a recombinant vector, a recombinant bacterium, a recombinant virus, or a transgenic cell line containing a nucleotide sequence encoding the RNA-guided nuclease;

[0091] The gRNA is capable of forming a complex with the RNA-guided nuclease and directing the complex to sequence-specific binding to the target RNA.

[0092] In some embodiments of the present disclosure, the gene editing system comprises:

[0093] (a) the gRNA disclosed herein, or a recombinant vector containing a nucleotide sequence encoding the gRNA; and

[0094] (b) an RNA-guided nuclease, or a recombinant vector containing a nucleotide sequence encoding the RNA-guided nuclease;

[0095] The gRNA is capable of forming a complex with the RNA-guided nuclease and directing the complex to sequence-specific binding to the target RNA.

[0096] In some embodiments of the present disclosure, (a) and (b) are two separate recombinant vectors. In some embodiments of the present disclosure, (a) and (b) are the same recombinant vector, i.e., the coding sequence of the RNA-guided nuclease and the coding sequence of the guide RNA are located on the same recombinant vector.

[0097] In some embodiments of the present disclosure, the recombinant vector comprises a regulatory sequence for regulating the expression of the coding sequence. In some embodiments, the recombinant vector comprises a regulatory sequence for regulating the expression of the coding sequence of the RNA-guided nuclease. In some embodiments, the recombinant vector comprises a regulatory sequence for regulating the expression of the coding sequence of the guide RNA. In some embodiments, the regulatory sequence is a promoter.

[0098] In some embodiments of the present disclosure, the gRNA is capable of forming a complex with the RNA-guided nuclease and directing the complex to bind to and cleave the target RNA.

[0099] In some embodiments of the present disclosure, the gRNA is any one of the following 1)-3):

[0100] 1) the gRNA comprises a targeting domain, wherein the targeting domain comprises a sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 98% or 100% identical to the sequence shown in SEQ ID No: 122;

[0101] 2) the gRNA comprises a targeting domain, wherein the targeting domain comprises a sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 98% or 100% identical to the sequence shown in positions 638-685 of SEQ ID No: 121;

[0102] 3) The gRNA includes a targeting domain, which comprises a sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 98% or 100% identical to any one of SEQ ID No: 1 to SEQ ID No: 8, SEQ ID No: 11 to SEQ ID No: 60.

[0103] In some embodiments of the present disclosure, the gRNA comprises a sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 98% or 100% identical to the sequence shown in any one of SEQ ID No: 1 to SEQ ID No: 8, SEQ ID No: 11 to SEQ ID No: 60.

[0104] In some embodiments of the present disclosure, the targeting domain of the gRNA comprises the sequence of SEQ ID No: 1 to SEQ ID No: 3, SEQ ID No: 6, SEQ ID No: 9 to SEQ ID No: 12, SEQ ID No: 16, SEQ ID No: 18 to SEQ ID No: 21, SEQ ID No: 23, SEQ ID No: 24, SEQ ID No: 28, SEQ ID No: 30, SEQ ID No: 34 to SEQ ID No: 36, SEQ ID No: 40 to SEQ ID No: 42, SEQ ID No: 51, SEQ ID No: 55, SEQ ID No: 61 to SEQ ID No: 76, SEQ ID No: 80 to SEQ ID No: 82, SEQ ID No: 84, SEQ ID No: 98, SEQ ID No: 100, SEQ ID No: 101, SEQ ID No: 102, SEQ ID No: 103, SEQ ID No: 104, SEQ ID No: 105 Any of the sequences shown in No: 104 has a sequence identity of at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 98% or 100%.

[0105] In some embodiments of the present disclosure, the targeting domain of the gRNA comprises a sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 98% or 100% identical to the sequence shown in SEQ ID No: 23. In some embodiments of the present disclosure, the targeting domain of the gRNA is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 98% or 100% identical to the sequence shown in SEQ ID No: 23. In some embodiments of the present disclosure, the sequence of the targeting domain of the gRNA is as shown in SEQ ID No: 23.

[0106] In some embodiments of the present disclosure, the amino acid sequence of the RNA-guided nuclease comprises a sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to the sequence shown in SEQ ID No: 107.

[0107] In some embodiments, the RNA-guided nuclease comprises one, two, three, four, five, or six mutations at positions corresponding to amino acid residues R210, H215, R750, H755, R785, and / or H790 of the reference protein (C13-2) set forth in SEQ ID No: 107. In some embodiments, the RNA-guided nuclease is mutated to A (alanine) at positions corresponding to amino acid residues R210, H215, R750, H755, R785, and / or H790 of the reference protein set forth in SEQ ID No: 107.

[0108] In some embodiments, the RNA-guided nuclease comprises any one or more of the following mutations at positions corresponding to the following amino acid residues of the reference protein as shown in SEQ ID No: 107: R11A, N34A, R35A, R47A, R58A, R63A, R64A, N68A, N87A, N265A, N274A, R276A, R290A, R294A, N299A, N303A, R 308A, R314A, R320A, R328A, N332A, R341A, N346A, R358A, N372A, N383A, N390A, N 394A, R47A+R290A, R47A+R314A, R290A+R314A, R47A+R290A+R314A, R308A+N68A, N394A+N68A, N87A+N68A, R308A+N265A, N394A+N265A, N87A+N265A, R308A+N68 A+N265A, N87A+N68A+N265A, T7S, A16S, S260E, A263K, M266I, N274K, F288Y, M3 02F, N303S, L304I, V305K, I311M, D313E, H324Y, P326S, H327V, N332Y, N346D, T353L, T360S, E365D, A373E, M380K, S382R, K395G, Y396D, D402L, D411E and S418K. Further, compared to the reference protein shown in SEQ ID No: 107, the Cas13 protein comprises the following mutations at the corresponding positions of the following amino acid residues of the reference protein shown in SEQ ID No: 107: D313E.

[0109] In some embodiments, the Cas13 protein can be obtained by introducing any one or more mutations at the following positions of the sequence shown in SEQ ID No: 107: R11, N34, R35, R47, R58, R63, R64, N68, N87, N265, N274, R276, R290, R294, N299, N303, R308, R314, R320, R328, N332, R341, N346, R358, N372, N383, N390, N394, R47+R290, R47+R314, R290+R314, R47+R290+R314, R308+N68, N 394+N68, N87+N68, R308+N265, N394+N265, N87+N265, R308+N68+N265, N87+N68+N265, T7, A16, S260, A263, M266, N274, F288, M30 2. N303, L304, V305, I311, D313, H324, P326, H327, N332, N346, T353, T360, E365, A373, M380, S382, K395, Y396, D402, D411, S418. Furthermore, the Cas13 protein can be obtained by introducing a mutation at position D313 of the sequence shown in SEQ ID No: 107.

[0110] In some embodiments, the Cas13 protein can be represented by SEQ ID The sequence shown in No: 107 is obtained by introducing any one or more of the following mutations at the following positions: R11A, N34A, R35A, R47A, R58A, R63A, R64A, N68A, N87A, N265A, N274A, R276A, R290A, R294A, N299A, N303A, R308A, R314A, R320A, R328A, N332A, R341A, N346A, R358A, N372A, N383A, N390A, N394A, R47A+R290A, R47A+R314A, R290A+R314A, R47A+R290A+R314A, R308A+N68A, N 394A+N68A, N87A+N68A, R308A+N265A, N394A+N265A, N87A+N265A, R308A+N68 A+N265A, N87A+N68A+N265A, T7S, A16S, S260E, A263K, M266I, N274K, F288Y, M3 02F, N303S, L304I, V305K, I311M, D313E, H324Y, P326S, H327V, N332Y, N346D, T353L, T360S, E365D, A373E, M380K, S382R, K395G, Y396D, D402L, D411E, and S418K.

[0111] In some embodiments, the Cas13 protein is a D313E mutant of the sequence shown in SEQ ID No: 107.

[0112] In some embodiments of the present disclosure, the gene editing system comprises:

[0113] (a) gRNA, or a nucleotide sequence encoding the gRNA; and

[0114] (b) an RNA-guided nuclease, or a nucleotide sequence encoding the RNA-guided nuclease;

[0115] The gRNA comprises a targeting domain that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 98% or 100% identical to the sequence shown in SEQ ID No: 23;

[0116] The RNA-guided nuclease comprises an amino acid sequence that is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID No: 107; wherein the RNA-guided nuclease is mutated to residue E at the position corresponding to amino acid residue D313 of the reference protein of SEQ ID No: 107;

[0117] The gRNA is capable of forming a complex with the RNA-guided nuclease and directing the complex to sequence-specific binding to the target RNA.

[0118] Fifthly, the present disclosure protects biological materials related to the above-mentioned gene editing system.

[0119] The biological material related to the above-mentioned gene editing system for which protection is sought in this disclosure is any one of the following X1) to X7):

[0120] X1) A vector system comprising the gene editing system, comprising a DNA sequence encoding the gRNA and a first regulatory sequence for regulating expression of the gRNA; and a DNA sequence encoding the RNA-guided nuclease and a second regulatory sequence for regulating expression of the RNA-guided nuclease;

[0121] X2) an adeno-associated virus vector comprising the gene editing system, comprising a DNA sequence encoding the RNA-guided nuclease and the gRNA;

[0122] X3) A lipid nanoparticle comprising the gene editing system, comprising the gRNA and an mRNA encoding the RNA-guided nuclease;

[0123] X4) A lentiviral vector comprising the gene editing system, comprising the gRNA and an mRNA encoding the RNA-guided nuclease;

[0124] X5) A ribonucleoprotein complex comprising the gene editing system, which is formed by the gRNA and the nuclease guided by the RNA;

[0125] X6) A virus-like particle comprising the gene editing system, comprising a ribonucleoprotein complex formed by the gRNA and a nuclease guided by the RNA;

[0126] X7) A eukaryotic cell comprising the above-mentioned gene editing system.

[0127] In some embodiments of the present disclosure, the gRNA is capable of forming a complex with the RNA-guided nuclease and directing the complex to bind to the target RNA in a sequence-specific manner. In some embodiments of the present disclosure, the gRNA is capable of forming a complex with the RNA-guided nuclease and directing the complex to bind to and cleave the target RNA.

[0128] In some embodiments of the present disclosure, the regulatory sequence in the vector system is a promoter or an enhancer.

[0129] In some embodiments of the present disclosure, the lentiviral vector is pseudotyped by an envelope protein, wherein the mRNA encoding the RNA-guided nuclease is linked to an aptamer sequence.

[0130] In some embodiments of the present disclosure, the RNA-guided nuclease in the virus-like particle is fused to the gag protein.

[0131] In some embodiments of the present disclosure, the eukaryotic cell is a mammalian cell, further can be a human, monkey or mouse cell, and further can be a human cell.

[0132] In some embodiments of the present disclosure, a vector system is provided, comprising a DNA sequence encoding the gRNA disclosed herein and a first regulatory sequence for regulating the expression of the gRNA; and a DNA sequence encoding an RNA-guided nuclease and a second regulatory sequence for regulating the expression of the RNA-guided nuclease. Further, in some embodiments, the gRNA is capable of forming a complex with the RNA-guided nuclease and directing the complex to bind to and cleave the target RNA in a sequence-specific manner. In some embodiments, the gRNA is capable of forming a complex with the RNA-guided nuclease and directing the complex to bind to and cleave the target RNA.

[0133] In some embodiments of the present disclosure, an adeno-associated viral vector is provided, comprising a DNA sequence encoding an RNA-guided nuclease and the gRNA of the present disclosure. Further, in some embodiments, the gRNA is capable of forming a complex with the RNA-guided nuclease and guiding the complex to sequence-specifically bind to the target RNA. In some embodiments, the gRNA is capable of forming a complex with the RNA-guided nuclease and guiding the complex to bind to and cleave the target RNA.

[0134] In some embodiments of the present disclosure, a lipid nanoparticle is provided, comprising the gRNA disclosed herein and an mRNA encoding an RNA-guided nuclease. Further, in some embodiments, the gRNA is capable of forming a complex with the RNA-guided nuclease and directing the complex to bind to and cleave the target RNA in a sequence-specific manner. In some embodiments, the gRNA is capable of forming a complex with the RNA-guided nuclease and directing the complex to bind to and cleave the target RNA.

[0135] In some embodiments of the present disclosure, a lentiviral vector is provided, comprising the gRNA disclosed herein and an mRNA encoding an RNA-guided nuclease. Further, in some embodiments, the gRNA is capable of forming a complex with the RNA-guided nuclease and directing the complex to bind to and cleave the target RNA in a sequence-specific manner. In some embodiments, the gRNA is capable of forming a complex with the RNA-guided nuclease and directing the complex to bind to and cleave the target RNA.

[0136] In some embodiments of the present disclosure, a ribonucleoprotein complex is provided, which is formed by the gRNA and the RNA-guided nuclease described herein. Further, in some embodiments, the gRNA is capable of forming a complex with the RNA-guided nuclease and guiding the complex to sequence-specifically bind to the target RNA. In some embodiments, the gRNA is capable of forming a complex with the RNA-guided nuclease and guiding the complex to bind to and cleave the target RNA.

[0137] In some embodiments of the present disclosure, a virus-like particle is provided, comprising a ribonucleoprotein complex formed by the gRNA and the RNA-guided nuclease of the present disclosure. Further, in some embodiments, the gRNA is capable of forming a complex with the RNA-guided nuclease and guiding the complex to sequence-specifically bind to the target RNA. In some embodiments, the gRNA is capable of forming a complex with the RNA-guided nuclease and guiding the complex to bind to and cleave the target RNA.

[0138] In some embodiments of the present disclosure, a eukaryotic cell comprising the gene editing system of the present disclosure is provided. Further, in some embodiments, the gRNA is capable of forming a complex with the RNA-guided nuclease and guiding the complex to sequence-specifically bind to the target RNA. In some embodiments, the gRNA is capable of forming a complex with the RNA-guided nuclease and guiding the complex to bind to and cleave the target RNA.

[0139] In a sixth aspect, the present disclosure protects a pharmaceutical composition.

[0140] The pharmaceutical composition claimed for protection in the present disclosure comprises the above-mentioned gRNA or the above-mentioned DNA molecule DNA sequence or the above-mentioned expression cassette, recombinant vector, recombinant bacteria, recombinant virus or transgenic cell line or the above-mentioned gene editing system or the above-mentioned biological material, and pharmaceutically acceptable excipients.

[0141] The drug delivery system includes but is not limited to: RNP delivery, liposome delivery, nanoparticle delivery, virus delivery, and extracellular vesicle delivery.

[0142] In the seventh aspect, the present disclosure requests protection for the new use of the above-mentioned gRNA or the above-mentioned DNA sequence or the above-mentioned expression cassette, recombinant vector, recombinant bacteria, recombinant virus or transgenic cell line or the above-mentioned gene editing system or the above-mentioned biological material or the above-mentioned pharmaceutical composition.

[0143] The present disclosure protects the use of the above-mentioned gRNA or the above-mentioned DNA sequence or the above-mentioned expression cassette, recombinant vector, recombinant bacterium, recombinant virus or transgenic cell line or the above-mentioned gene editing system or the above-mentioned biomaterial or the above-mentioned pharmaceutical composition in any one of the following Y1)-Y8):

[0144] Y1) cleaving one or more target RNA molecules or causing nicks in one or more target RNA molecules;

[0145] Y2) activating or upregulating one or more target RNA molecules;

[0146] Y3) inhibiting, downregulating or inactivating one or more target RNA molecules;

[0147] Y4) visualizing, labeling or detecting one or more target RNA molecules;

[0148] Y5) binding to one or more target RNA molecules;

[0149] Y6) transporting one or more target RNA molecules;

[0150] Y7) masking one or more target RNA molecules;

[0151] Y8) preparing a medicament for diagnosing, treating or preventing a disease or condition associated with the target RNA.

[0152] In an eighth aspect, the present disclosure claims a method for diagnosing, treating or preventing a disease or disorder associated with a target RNA.

[0153] The method for diagnosing, treating or preventing a disease or condition associated with a target RNA claimed in the present disclosure comprises the following steps: administering the above-mentioned gRNA or the above-mentioned DNA sequence or the above-mentioned expression cassette, recombinant vector, recombinant bacteria, recombinant virus or transgenic cell line or the above-mentioned gene editing system or the above-mentioned biological material or the above-mentioned pharmaceutical composition to a sample of a subject in need or to a subject in need.

[0154] In any of the above applications or methods, the target RNA is PTBP1 RNA, specifically human PTBP1 RNA, mouse PTBP1 RNA or monkey PTBP1 RNA.

[0155] The disease or disorder associated with the target RNA may be a disease or disorder caused by abnormal expression of the target RNA.

[0156] This disclosure provides a guide RNA (gRNA) targeting PTBP1 RNA, a gene editing system, and applications thereof. The gene editing system comprises a guide RNA (gRNA) targeting a target RNA, such as human, mouse, or monkey PTBP1 RNA, and an RNA-guided nuclease. The target RNA comprises a targeting domain comprising a sequence set forth in any one of SEQ ID Nos: 1-8 or 11-105. The gene editing system provided herein can be used to diagnose, treat, or prevent diseases or conditions associated with the target RNA. BRIEF DESCRIPTION OF THE DRAWINGS

[0157] Figure 1 is a schematic diagram of the location of the corresponding target sequence of a portion of the gRNA targeting human cells on a specific target RNA, namely, the human PTBP1 mRNA transcript variant (NCBI NM_002819.5).

[0158] Figure 2 shows the location of target sequences corresponding to mouse cell-targeted gRNAs on a specific target RNA, namely, the mouse PTBP1 mRNA transcript variant (NCBI NM_001077363.3). Among them, the highly active M55-M57, M59, and M62 gRNAs target 638-685 nt.

[0159] Figure 3 is a schematic diagram of the locations of target sequences corresponding to monkey cell-targeted gRNAs on a specific target RNA, namely, monkey PTBP1 mRNA transcript variant (NCBI XM_015122300.2). Among them, multiple gRNAs targeting 627nt-3697nt (starting from HMK74 and ending at HMK87) showed knockdown activity.

[0160] Figure 4 shows that in 293T cells, under the set threshold conditions, there was no off-target effect after combined editing of the M2-25 mutant and H30gRNA.

[0161] Figure 5 shows that in 293T cells, under the set threshold conditions, there was no off-target effect after combined editing of C13-2 protein and H30gRNA.

[0162] Figure 6 shows that after editing with the C13-2-M2-25 mutant protein combined with H30gRNA in the Parkinson's disease model monkey, upregulation of markers such as DCX-1, astrocyte transdifferentiation markers, and downregulation of astrocyte markers GFAP-2 and S100B were detected in the substantia nigra region.

[0163] Figure 7 shows the reprogramming trajectory captured by scRNA-Seq using the C13-2-M2-25+H30 gRNA drug. The C13-2-M2-25+H30 gRNA drug promoted cell type changes, particularly the increase in midbrain neuroblasts and neurons, indicating transdifferentiation.

[0164] Figure 8 shows that in a Parkinson's disease mouse model, after editing with the C13-2-M2-25 mutant protein combined with M55gRNA, the number of rotations in the "dose 2" experimental group was significantly lower than that in the negative control group at 1-3 months, with a statistically significant difference (P<0.05). The number of rotations in the "dose 1" experimental group was also numerically lower than that in the negative control group. At 3 months, the "dose 2" experimental group had a significantly longer rotation time than the negative control group, with a statistically significant difference (P<0.05). DETAILED DESCRIPTION

[0165] Definition section:

[0166] As used herein, the terms guide polynucleotide, gene editing system guide RNA, guide RNA, guide RNA and gRNA are used interchangeably. The term guide RNA is used to refer to a molecule that forms a complex with the RNA-guided nuclease in the gene editing system and guides the sequence-specific binding of the complex to the target sequence. The guide RNA comprises a guide sequence that can hybridize with the target sequence. When the RNA-guided nuclease is a Cas protein, especially a Cas13 protein, the guide RNA typically comprises a directional repeat sequence connected to the guide sequence.

[0167] As used herein, the terms "guide sequence" and "targeting domain" are used interchangeably and refer to a contiguous nucleotide sequence in a gRNA that has partial or full complementarity with a target sequence in a target RNA and can hybridize to the target sequence in the target RNA through base pairing promoted by an RNA-guided nuclease. Full complementarity between the guide sequence and the target sequence described in the present disclosure is not required, as long as there is sufficient complementarity to cause hybridization and promote the formation of a gene editing complex.

[0168] When referring to a gRNA, the term backbone sequence may comprise or consist of direct repeat sequences.

[0169] Suitable direct repeat (DR) sequences may be present in the CRISPR locus structure of prokaryotes (such as bacteria and archaea) and obtained through experimental screening; they may also be obtained through sequence modification or optimization on this basis, non-limiting examples of which include the deletion, replacement or addition of 1, 2, 3, 4 or more complementary base pairs in the complementary double-stranded region of the secondary structure of the DR sequence, and the deletion, replacement or addition of nucleotides on the loop of the stem-loop structure of the secondary structure of the DR sequence (for example, an aptamer sequence may be inserted into the loop). The size of the direct repeat sequence is usually tens of nucleotides, and some of its fragments are reverse complementary to each other, which means that a secondary structure is formed inside the RNA molecule, such as a stem-loop structure (often called a hairpin structure), and other fragments are unstructured. When the RNA-guided nuclease is a Cas protein, the direct repeat sequence is a constant part of the gRNA molecule, which contains a strong secondary structure, which is conducive to the interaction between the Cas protein and the gRNA molecule.

[0170] The term "hybridization" or "hybridization" refers to the process in which fully or partially complementary polynucleotide chains come together to form a double-stranded structure or region under suitable hybridization conditions, including the association between the nucleic acids caused by hydrogen bonds. As used herein, the term hybridization includes situations in which double-stranded structures or regions contain one or more protrusions or mispairings. The intensity of hybridization and hybridization (that is, the intensity of association between nucleic acids) is affected by factors such as the degree of complementarity between the nucleic acids, the stringency of the conditions involved, and the Tm of the formed hybrid. Although hydrogen bonds are generally formed between adenine and thymine, adenine and uracil, or between cytosine and guanine, other non-classical base pairs can also form hydrogen bonds. It is contemplated that the modified nucleotides can form hydrogen bonds that allow or promote hybridization using non-classical approaches.

[0171] As used herein, the term target RNA refers to a polynucleotide containing a target sequence, indicating a specific sequence or its reverse complement that one wishes to bind, target, or modify using a gene editing system. For example, it can be a complete mature mRNA molecule or a pre-mRNA molecule.

[0172] As used herein, the term target sequence refers to a short sequence in a target RNA molecule that is complementary (completely complementary or partially complementary) to the guide sequence of the gRNA molecule. The gene editing complex is specifically located at the target sequence through the guide sequence and performs the corresponding function at or near this position. The length of the target sequence is often tens of nt (nucleotides), for example, about 10nt, about 20nt, about 30nt, about 40nt, about 50nt, about 60nt.

[0173] As used herein, the terms cleavage and cleaving refer to breaking covalent bonds (eg, covalent phosphodiester bonds) in the ribosyl phosphodiester backbone of a polynucleotide.

[0174] The ability of a guide RNA to direct a complex to bind specifically to the sequence of a target RNA can be assessed by any suitable assay. For example, components of a gene editing system sufficient to form a CRISPR complex, including the guide RNA to be tested, can be provided to a host cell having a corresponding target RNA molecule, such as by transfection of a vector encoding the components of the CRISPR complex, and then preferential cleavage within the target sequence can be assessed. Similarly, cleavage of a target RNA sequence can be assessed in a test tube by providing a target RNA, components of a CRISPR complex, including the guide RNA to be tested and a control guide RNA that is different from the test guide RNA, and comparing the ability to bind to the target RNA or the rate at which the target RNA is cut between the guide RNA to be tested and the control guide RNA. The ability of a guide RNA to direct a complex to cut a target RNA can also be assessed by the assays described above.

[0175] The term RNA-guided nuclease refers to a polypeptide that binds to a specific target RNA sequence in a sequence-specific manner and is guided to the target RNA by a guide RNA that complexes with the polypeptide and hybridizes to a target sequence on the target RNA. Cleavage of the target sequence by the RNA-guided nuclease can result in strand breaks. Although RNA-guided nucleases can cleave target sequences upon binding, the term RNA-guided nuclease also includes nuclease-inactive RNA-guided nucleases that are able to bind but not cleave the target sequence.

[0176] The RNA-guided nucleases disclosed herein include, but are not limited to, wild-type RNA-guided nucleases (e.g., Cas9 proteins such as SpCas9, SaCas9, NmeCas9, SauriCas9, Cas12a proteins such as AsCpf1, Cas12b proteins, Cas12c proteins, Cas12d proteins, Cas12e proteins, Cas12f proteins, Cas12g proteins, Cas12h proteins, Cas12i proteins, Cas12j proteins, Cas12k proteins, Cas12l proteins, Cas12m proteins, Cas13a proteins such as LsCas13a, LwaCas13a, Cas13b proteins such as PspCas13b, BzCas13b, PbCas13b, Cas13X.1, Cas13X.2, Cas13Y.1, Cas13Y.2, Cas13Y.3, Cas13Y.4, Cas13Y.5, Cas13Y.6, Cas13Y.7, Cas13Y.8, Cas13Y.9, Cas13Y.10, Cas13Y.11, Cas13Y.12, Cas13Y.13, Cas13Y.14, Cas13Y.15, Cas13Y.16, Cas13Y.17, Cas13Y.18, Cas13Y.19, Cas13Y.21, Cas13Y.19, Cas13Y.22, Cas13Y.11, Cas13Y.17, Cas13Y.18, Cas13Y.19, Cas13Y.23, Cas13Y.19, Cas13Y.11, Cas13Y.11, Cas13Y.11, Cas13Y.12, Cas13Y.1 3Y.2, Cas13Y.3, Cas13c protein, Cas13d protein such as CasRx, C13-2, EsCas13d, RspCas13d, etc.), variants thereof (e.g., mutants with complete loss of cleavage activity such as RxxxxH motif mutants of Cas13, mutants with partial loss of cleavage activity such as Cas9 nickase or Cas12 nickase, mutants with improved cleavage activity, mutants with reduced off-target effects, mutants with reduced side cutting effects), or functional fragments thereof (e.g., only maintaining the binding function to the target RNA without the function of cutting the target RNA, such as the RNA binding domain of a complete Cas protein), or fusion proteins (e.g., the aforementioned wild-type nuclease, mutant or functional fragment is fused with NLS, NES, adenosine deaminase, cytidine deaminase, translation inhibition domain, translation activation domain or methylation domain). The above-mentioned wild-type Cas12g can generally target RNA, which can be combined with the gRNA disclosed herein to target the target RNA. For nucleases that usually do not target RNA but target DNA, they can be modified by editing systems and then use the guide sequences disclosed herein to achieve targeting of the target RNA, for example, through PAMmer technology (https: / / doi.org / 10.1016 / j.cell.2016.02.054). Such editing systems also fall within the scope of protection of this application.

[0177] As used herein, the term Cas protein is a CRISPR-associated (Cas) polypeptide or protein that, when complexed or functionally combined with one or more guide RNAs, can be guided to a target sequence in a target RNA and can sometimes subsequently bind to or cleave the target RNA.

[0178] As used herein, the term "sequence identity" or "percent identity" refers to the matching of sequences between two polypeptides or between two nucleic acids. When a certain position in the two sequences being compared is occupied by the same base or amino acid monomer subunit (e.g., a certain position in each of the two DNA sequences is occupied by adenine, or a certain position in each of the two polypeptides is occupied by lysine), then the molecules are identical at that position. The "percent sequence identity" between two sequences is a function of the number of matching positions shared by the two sequences divided by the number of positions compared × 100%. For example, if 6 out of 10 positions in the two sequences match, then the two sequences have 60% sequence identity. Typically, comparisons are made when two sequences are aligned to produce maximum sequence identity. Such comparisons can be made using published and commercially available alignment algorithms and programs, such as, but not limited to, ClustalΩ, MAFFT, Probcons, T-Coffee, Probalign, BLAST, which one of ordinary skill in the art can reasonably select for use. Those skilled in the art can determine appropriate parameters for aligning sequences, including, for example, any algorithms needed to achieve better alignment or optimal comparison over the entire length of the sequences being compared, as well as any algorithms needed to achieve better alignment or optimal comparison over a portion of the sequences being compared.

[0179] As used herein, the term "recombinant vector" refers to a nucleic acid molecule composed of nucleic acid fragments linked together by molecular biology techniques.

[0180] As used herein, the term regulatory sequence is intended to include promoters, enhancers, internal ribosome entry sites (IRES), and other expression control elements (e.g., transcription termination signals, such as polyadenylation signals and poly-U sequences). Regulatory sequences include those elements that direct the continuous expression of a nucleotide sequence in many types of host cells and those elements that direct the expression of a nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). Tissue-specific promoters can direct expression primarily in desired tissues of interest such as muscle, neurons, bones, skin, blood, specific organs (e.g., liver, pancreas), or specific cell types (e.g., neuronal cells, lymphocytes). Regulatory sequences can also direct expression in a time-dependent manner such as a cell cycle-dependent or developmental stage-dependent manner, which may or may not be tissue-specific or cell-type-specific. The term regulatory sequence also encompasses enhancer elements such as WPRE, CMV enhancer, SV40 enhancer, and the intron sequence between exons 2 and 3 of rabbit β-globin. Those skilled in the art will appreciate that the design of the expression vector can depend on factors such as the selection of the host cell to be transformed, the desired expression level, and the like. The vector can be introduced into a host cell to produce the RNA-guided nucleases and / or guide RNAs described herein.

[0181] As used herein, the term pharmaceutically acceptable excipient refers to a diluent, adjuvant, pharmaceutical carrier or other excipient administered together with the active ingredient. Its selection depends on the method of administration of purposes and expectation. Excipient should not be incompatible with the active ingredient, for example, producing any undesirable biological effect or interacting with any other component of the pharmaceutical composition in a harmful manner. Pharmaceutical composition can be prepared by known methods in the field of pharmaceutical preparation.

[0182] When referring to an RNA sequence, the "t" in the sequence is used interchangeably with the "u". When referring to a "guide sequence", the "t" in the sequence is used interchangeably with the "u". When referring to a "direct repeat sequence", the "t" in the sequence is used interchangeably with the "u".

[0183] guide RNA

[0184] In some embodiments of the present disclosure, the guide RNA is capable of forming a complex with an RNA-guided nuclease (also referred to as a gene editing complex) and guiding the sequence-specific binding of the complex to the target RNA.

[0185] In some embodiments of the present disclosure, the guide RNA is capable of forming a complex with an RNA-guided nuclease and directing the complex to bind to and cleave the target RNA.

[0186] In some embodiments of the disclosure, the complex reduces the level of the target RNA in the cell.

[0187] In some embodiments of the present disclosure, the complex reduces the level of the target RNA in the cell by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99%. The reduction in the level of the target RNA can be tested using conventional methods in the art; including but not limited to qPCR methods, such as RT-qPCR methods. The RNA levels of untreated cells or cells treated with a gene editing system targeting a non-mammalian genome can be tested as a negative control, and the target RNA knockdown level of the experimental group compared to the negative control is calculated. The experimental group and the negative control group can be edited using the same Cas protein (e.g., by expressing the same Cas protein) and gRNAs containing different guide sequences to compare the difference in target RNA levels; for example, the experimental group uses C13-2 and the gRNA claimed in the present disclosure for editing, and the negative control group uses C13-2 and gRNAs targeting non-mammalian genomes for editing. The experimental group can also be compared with known editing tools, such as the CasRx+3sg9gRNA+3sg10gRNA editing tool.

[0188] In some embodiments of the present disclosure, the complex reduces the level of the target RNA in the cell by at least 5%. In some embodiments of the present disclosure, the complex reduces the level of the target RNA in the cell by at least 40%. In some embodiments of the present disclosure, the complex reduces the level of the target RNA in the cell by at least 80%. In some embodiments of the present disclosure, the complex reduces the level of the target RNA in the cell by at least 85%. In some embodiments of the present disclosure, the complex reduces the level of the target RNA in the cell by at least 90%.

[0189] In some embodiments of the present disclosure, the number of off-target genes when the complex binds and cuts the target RNA is less than 40, less than 35, less than 30, less than 25, less than 20, less than 19, less than 18, less than 17, less than 16, less than 15, less than 14, less than 13, less than 12, less than 11, less than 10, less than 9, less than 8, less than 7, less than 6, less than 5, less than 4, less than 3, less than 2 or less than 1. The number of off-target genes can be determined by conventional methods in this area. In some embodiments, the number of off-target genes is determined by taking the intersection of the differentially expressed gene set determined by the experiment and the off-target gene set predicted by the program. In some embodiments, the number of off-target genes is determined by taking the intersection of the differentially expressed gene set determined by RNA sequencing (RNA-Seq) and the off-target gene set predicted by the program. Off-target genes can be predicted using off-target gene prediction programs known in the art under conventional parameter settings. As a non-limiting example, the program predicts a target gene in the whole genome and whole cDNA sequence of the target species (e.g., Homo sapiens, Mus musculus, or Macaca mulatta) using the EMBOSS-water program, setting the parameters to gap_extend = 0.5 & gap_extend = 10, using the forward and reverse strands of the gRNA guide sequence for alignment, filtering the prediction results, and obtaining predicted potential target genes (including target genes and off-target genes).

[0190] In some embodiments of the present disclosure, the RNA-guided nuclease is a Cas protein. In some embodiments, the cleavage activity of the RNA-guided nuclease is completely or partially lost.

[0191] In some embodiments of the present disclosure, the RNA-guided nuclease is a Cas protein.

[0192] In some embodiments of the present disclosure, the RNA-guided nuclease is a Cas protein, and the guide RNA comprises a guide sequence and a direct repeat sequence.

[0193] In some embodiments of the present disclosure, the Cas protein is Cas9 protein, Cas12 protein or Cas13 protein. In some embodiments, the Cas protein is Cas12a protein, Cas12b protein, Cas12c protein, Cas12d protein, Cas12e protein, Cas12f protein, Cas12g protein, Cas12h protein, Cas12i protein, Cas12j protein, Cas12k protein.

[0194] In some embodiments of the present disclosure, the Cas protein is a Cas13 protein.

[0195] In some embodiments of the present disclosure, the Cas protein is Cas13a protein, Cas13b protein, Cas13c protein or Cas13d protein. In some embodiments of the present disclosure, the Cas protein is a Cas13a protein, Cas13b protein or Cas13c protein in which the catalytic center RxxxxH motif of two HEPN domains carries a mutation, and the cleavage activity of these Cas proteins is completely or partially lost. In some embodiments, the Cas protein is a CasRx protein. In some embodiments, the Cas protein is a dCasRx in which both HEPN domains carry mutations (R239A, H244A of HEPN-1 and R858A, H863A of HEPN-2).

[0196] In some embodiments of the present disclosure, the Cas protein comprises the sequence shown in SEQ ID NO:107.

[0197] In some embodiments of the present disclosure, the RNA-guided nuclease comprises any one or more of the following: a subcellular localization signal, a deaminase domain, a translation activation domain, a translation repression domain, an RNA methylation domain, an RNA demethylation domain, a nuclease domain, a splicing factor domain, a reporter tag, and an affinity tag.

[0198] In some embodiments of the disclosure, the guide sequence comprises 20-40, 20-35, 20-30, or 25-30 nucleotides.

[0199] In some embodiments of the present disclosure, the guide sequence hybridizes to the target RNA with no more than 6, no more than 5, no more than 4, no more than 3, no more than 2, or no more than 1 mismatch.

[0200] In some embodiments, the guide sequence has 100% complementarity with the target RNA, but the guide sequence can have less than 100% complementarity with the target RNA, e.g., at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% complementarity.

[0201] In some embodiments of the present disclosure, the guide sequence has 100% sequence identity with the target RNA, i.e., is fully complementary.

[0202] In some embodiments of the present disclosure, the guide sequence is located at the 3' end or 5' end of the direct repeat sequence. In some embodiments of the present disclosure, the guide sequence is located at the 3' end of the direct repeat sequence. In some embodiments of the present disclosure, the guide sequence is located at the 5' end of the direct repeat sequence.

[0203] In some embodiments of the present disclosure, the direct repeat sequence comprises the sequence shown in SEQ ID NO: 109. In some embodiments of the present disclosure, the direct repeat sequence consists of the sequence shown in SEQ ID NO: 109.

[0204] In some embodiments of the present disclosure, the guide RNA comprises an aptamer sequence.

[0205] In some embodiments of the present disclosure, the aptamer sequence is inserted into the loop of the stem-loop structure of the direct repeat sequence secondary structure of the guide RNA.

[0206] In some embodiments of the present disclosure, the guide RNA comprises modified nucleotides. The modifications include, but are not limited to, 2'-O-methyl, 2'-O-methyl-3'-phosphorothioate or 2'-O-methyl-3'-thio PACE modifications. In some embodiments of the present disclosure, the guide RNA comprises modified nucleotides selected from deoxyribonucleotides and locked nucleic acids (LNA). In some embodiments, the guide RNA comprises at least one chemically modified nucleotide. In some embodiments, the guide RNA is a hybrid RNA-DNA guide, i.e., some RNA nucleotides in the guide RNA are replaced by DNA nucleotides. In some embodiments, the guide RNA is a hybrid RNA-LNA (locked nucleic acid) guide, i.e., some RNA nucleotides in the guide RNA are replaced by LNA nucleotides.

[0207] In some embodiments, multiple guide RNAs are part of an array (which can be part of a vector, such as a viral vector or plasmid). For example, a guide array comprising the sequence DR-spacer-DR-spacer-DR-spacer can include three unique unprocessed guide RNAs (one for each DR-spacer sequence). Once introduced into a cell or cell-free system, the array is processed into three separate mature guide RNAs by RNA-guided nucleases such as Cas proteins. This allows for multiplexing, such as delivering multiple guide RNAs to a cell or system to target multiple target RNAs or multiple regions within a single target RNA.

[0208] In some embodiments of the present disclosure, the target RNA is located in the nucleus and / or cytoplasm of a eukaryotic cell.

[0209] target RNA

[0210] The gene editing systems and compositions disclosed herein can be used to target one or more target RNA molecules, such as target RNA molecules present in a biological sample. In some embodiments, the target RNA is pre-mRNA or mRNA (mature mRNA).

[0211] In some embodiments of the present disclosure, the target RNA is PTBP1 RNA. In some embodiments of the present disclosure, the target RNA is human PTBP1 RNA, mouse PTBP1 RNA, or monkey PTBP1 RNA.

[0212] In some embodiments of the present disclosure, the target RNA is PTBP1 RNA or a fragment thereof; optionally, the PTBP1 RNA is derived from humans, mice or monkeys.

[0213] In some embodiments of the present disclosure, the target RNA is PTBP1 mRNA or a fragment thereof; optionally, the PTBP1 mRNA is derived from humans, mice or monkeys.

[0214] In some embodiments of the present disclosure, the target RNA is PTBP1 pre-mRNA or a fragment thereof; optionally, the PTBP1 pre-mRNA is derived from humans, mice or monkeys.

[0215] In some embodiments of the present disclosure, the gene editing systems described herein can be used to increase the expression level of PTBP1 RNA; for example, using an RNA-guided nuclease fused to a translation activation domain, under the guidance of a gRNA, to contact PTBP1 RNA and increase its translation level. In some embodiments, the gene editing systems described herein can be used to decrease the expression level of PTBP1 RNA; for example, using an RNA-guided nuclease, under the guidance of a gRNA, to contact and cleave PTBP1 RNA. In some embodiments, the gene editing systems described herein can be used to decrease the expression level of PTBP1 RNA in cells (including but not limited to astrocytes and Müller glia).

[0216] RNA-guided nucleases

[0217] In some embodiments of the present disclosure, the RNA-guided nuclease is a Cas protein.

[0218] The RNA-guided nucleases disclosed herein include, but are not limited to, wild-type RNA-guided nucleases (e.g., Cas9 proteins such as SpCas9, SaCas9, NmeCas9, SauriCas9, Cas12a proteins such as AsCpf1, Cas12b proteins, Cas12c proteins, Cas12d proteins, Cas12e proteins, Cas12f proteins, Cas12g proteins, Cas12h proteins, Cas12i proteins, Cas12j proteins, Cas12k proteins, Cas12l proteins, Cas12m proteins, Cas13a proteins such as LsCas13a, LwaCas13a, Cas13b proteins such as Psp Cas13b, BzCas13b, PbCas13b, Cas13X.1, Cas13X.2, Cas13Y.1, Cas13Y.2, Cas13Y.3, Cas13c protein, Cas13d protein such as CasRx, C13-2, EsCas13d, RspCas13d, etc.), variants thereof (e.g., mutants with complete loss of cleavage activity such as RxxxxH motif mutants of Cas13, mutants with partial loss of cleavage activity such as Cas9 nickase or Cas12 nickase, mutants with improved cleavage activity, mutants with reduced off-target effects, mutants with reduced side cutting effects), or functional fragments thereof (e.g., only maintaining the binding function to the target RNA without the function of cleaving the target RNA, such as the RNA binding domain of a complete Cas protein), or fusion proteins (e.g., the aforementioned wild-type nuclease, mutant or functional fragment fused with NLS, NES, adenosine deaminase, cytidine deaminase, translation inhibition domain, translation activation domain or methylation domain). The wild-type Cas12g described above can generally target RNA, which can be combined with the gRNA disclosed herein to target the target RNA. For nucleases that generally do not target RNA but target DNA, the target RNA can be targeted by modifying the editing system and then utilizing the guide sequence disclosed herein, for example, by PAMmer technology (https: / / doi.org / 10.1016 / j.cell.2016.02.054). Such editing systems also fall within the scope of protection of this application.

[0219] In some embodiments of the present disclosure, the RNA-guided nuclease comprises any one or more of the following fusion domains: a subcellular localization signal, a deaminase domain, a translation activation domain, a translation repression domain, an RNA methylation domain, an RNA demethylation domain, a nuclease domain, a splicing factor domain, a reporter tag, and an affinity tag.

[0220] In some embodiments of the present disclosure, the Cas9, Cas12 or Cas13 comprises any one or more of the following fusion domains: a subcellular localization signal, a deaminase domain, a translation activation domain, a translation repression domain, an RNA methylation domain, an RNA demethylation domain, a nuclease domain, a splicing factor domain, a reporter tag and an affinity tag.

[0221] Exemplary fusion domains (e.g., fused heterologous protein domains) include domains that can cleave RNA (e.g., PIN endonuclease domains, NYN domains, SMR domains from SOT1, or RNase domains from staphylococcal nuclease), domains that can affect RNA stability (e.g., tristetraprolin (TTP) or domains from UPF1, EXOSC5, and STAU1), domains that can edit nucleotides or ribonucleotides (e.g., cytidine deaminases, PPR proteins, adenosine deaminases, ADAR family proteins, or APOBEC family proteins), domains that can activate translation (e.g., eIF4E and other translation initiation factors, yeast poly(A) binding protein, or domains of GLD2), domains that can inhibit translation (e.g., Pumilio or FBF). These proteins may be PUF proteins, deadenylases, CAF1, Argonaute proteins), domains that can methylate RNA (e.g., domains from m6A methyltransferase factors such as METTL14, METTL3, or WTAP), domains that can demethylate RNA (e.g., human alkylation repair homolog 5), domains that can affect splicing (e.g., the RS-rich domain of SRSF1, the Gly-rich domain of hnRNP A1, the alanine-rich motif of RBM4, or the proline-rich motif of DAZAP1), domains that can enable affinity purification or immunoprecipitation (e.g., FLAG, HA, biotin, or HALO tags), and domains that can enable proximity-based protein labeling and recognition (e.g., biotin ligases such as BirA or peroxidases such as APEX2 to biotinylate target DNA-interacting proteins).

[0222] In some embodiments, the fusion domain comprises an adenosine deaminase domain. In some embodiments, a Cas13 protein having a mutant HEPN domain or a catalytically inactive Cas13 protein is covalently linked or fused to an adenosine deaminase domain to guide the A-to-I deaminase activity of RNA transcripts in mammalian cells. For example, an adenosine deaminase domain engineered for targeted A-to-I RNA editing based on ADAR2 is fused. In other embodiments, the adenosine deaminase domain is covalently linked or fused to an adapter protein that is capable of binding to an aptamer sequence inserted into or attached to a guide RNA, thereby allowing the adenosine deaminase domain to be non-covalently linked to the Cas13 protein complexed with the guide RNA.

[0223] In some embodiments, the fusion domain comprises a cytosine deaminase domain. In some embodiments, the Cas13 protein with a mutant HEPN domain or a catalytically inactive Cas13 protein is covalently linked or fused to a cytosine deaminase domain to guide the C-to-U deaminase activity of RNA transcripts in mammalian cells. For example, a cytosine deaminase domain for targeting C-to-U RNA editing evolved using ADAR2 is used. In other embodiments, the cytosine deaminase domain is covalently linked or fused to an adapter protein that is capable of binding to an aptamer sequence inserted into or attached to a guide RNA, thereby allowing the cytosine deaminase domain to be non-covalently linked to the Cas13 protein complexed with the guide RNA.

[0224] In some embodiments, the fusion domain comprises a splicing factor domain. In some embodiments, the Cas13 protein with a mutant HEPN domain or a catalytically inactive Cas13 protein is covalently linked or fused to a splicing factor domain to guide the alternative splicing of the target RNA in a mammalian cell. Non-limiting examples of splicing factor domains include the RS-rich domain of SRSF1, the Gly-rich domain of hnRNPA1, the alanine-rich motif of RBM4, or the proline-rich motif of DAZAP1. In other embodiments, the splicing factor domain is covalently linked or fused to a linker protein that is capable of binding to an aptamer sequence inserted into or attached to the guide RNA, thereby allowing the splicing factor domain to be non-covalently linked to the Cas13 protein compounded with the guide RNA.

[0225] In some embodiments, the fusion domain includes a translation activation domain. In some embodiments, the Cas13 protein with a mutant HEPN domain or a catalytically inactive Cas13 protein is covalently linked or fused to a translation activation domain to activate or increase the expression of the target RNA. Non-limiting examples of translation activation domains include eIF4E and other translation initiation factors, yeast poly (A) binding protein or the domain of GLD2. In other embodiments, the translation activation domain is covalently linked or fused to a linker protein that can bind to an aptamer sequence inserted into or attached to the guide RNA, thereby allowing the translation activation domain to be non-covalently linked to the Cas13 protein compounded with the guide RNA.

[0226] In some embodiments, the fusion domain comprises a translation inhibition domain. In some embodiments, the Cas13 protein with a mutant HEPN domain or a catalytically inactive Cas13 protein is covalently linked or fused to a translation inhibition domain to inhibit or reduce the expression of the target RNA. Non-limiting examples of translation inhibition domains include Pumilio or FBF PUF proteins, deadenylase, CAF1, Argonaute proteins. In other embodiments, the translation inhibition domain is covalently linked or fused to a linker protein that is capable of binding to an aptamer sequence inserted into or attached to the guide RNA, thereby allowing the translation inhibition domain to be non-covalently linked to the Cas13 protein complexed with the guide RNA.

[0227] In some embodiments, the fusion domain comprises an RNA methylation domain. In some embodiments, a Cas13 protein having a mutant HEPN domain or a catalytically inactive Cas13 protein is covalently linked or fused to an RNA methylation domain for methylation of the target RNA. Non-limiting examples of RNA methylation domains include m6A domains, such as METTL14, METTL3, or WTAP. In other embodiments, the RNA methylation domain is covalently linked or fused to an adapter protein that is capable of binding to an aptamer sequence inserted into or attached to the guide RNA, thereby allowing the RNA methylation domain to be non-covalently linked to the Cas13 protein complexed with the guide RNA.

[0228] In some embodiments, the fusion domain comprises an RNA demethylation domain. In some embodiments, a Cas13 protein having a mutant HEPN domain or a catalytically inactive Cas13 protein is covalently linked or fused to an RNA demethylation domain for demethylation of the target RNA. Non-limiting examples of RNA demethylation domains include human alkylation repair homolog 5 or ALKBH5. In other embodiments, the RNA demethylation domain is covalently linked or fused to an adapter protein that is capable of binding to an aptamer sequence inserted into or attached to the guide RNA, thereby allowing the RNA demethylation domain to be non-covalently linked to the Cas13 protein complexed with the guide RNA.

[0229] In some embodiments, the fusion domain comprises a ribonuclease domain. In some embodiments, a Cas13 protein having a mutant HEPN domain or a catalytically inactive Cas13 protein is covalently linked or fused to a ribonuclease domain to cleave the target RNA. Non-limiting examples of ribonuclease domains include a PIN endonuclease domain, a NYN domain, an SMR domain from SOT1, or an RNase domain from Staphylococcus nuclease.

[0230] In some embodiments, the fusion domain includes an affinity tag or a reporter domain. In some embodiments, Cas13 protein is covalently linked to or fused to a reporter domain, such as a fluorescent protein. Non-limiting examples of reporter domains include GST, HRP, CAT, GFP, HcRed, DsRed, CFP, YFP, BFP. In some embodiments, Cas13 protein is covalently linked to or fused to an affinity tag such as a purification tag. Non-limiting examples of affinity tags include HA-tags, His-tags (e.g., 6-His), Myc-tags, E-tags, S-tags, calmodulin tags, FLAG-tags, GST-tags, MBP-tags, Halo tags, or biotin.

[0231] In some embodiments of the present disclosure, the fusion domain is located at the N-terminus, C-terminus, or both the N-terminus and the C-terminus of the RNA-guided nuclease. In some embodiments of the present disclosure, the N-terminus, C-terminus, or both the N-terminus and the C-terminus of the RNA-guided nuclease are fused with 0, 1, 2, 3, 4 or more fusion domains, respectively.

[0232] In some embodiments of the present disclosure, the RNA-guided nuclease is covalently linked to the fusion domain with or without a linker sequence; that is, the RNA-guided nuclease is directly covalently linked to the fusion domain (without a linker sequence) or covalently linked via a linker sequence. Typically, the linker sequence consists of 1-100, 1-50, 1-30, 1-20, 1-10, or 1-5 amino acids.

[0233] In some embodiments of the present disclosure, the RNA-guided nuclease comprises a subcellular localization signal.

[0234] In some embodiments of the present disclosure, the RNA-guided nuclease comprises a subcellular localization signal and a deaminase domain.

[0235] In some embodiments of the present disclosure, the subcellular localization signal is selected from a nuclear localization signal and a nuclear export signal.

[0236] In some embodiments, the RNA-guided nuclease is fused to at least one subcellular localization signal. Exemplary subcellular localization signals include organelle localization signals, such as a nuclear localization signal (NLS), a nuclear export signal (NES), or a mitochondrial localization signal.

[0237] In some embodiments, the RNA-guided nuclease is fused to at least one heterologous NLS. In some embodiments, the RNA-guided nuclease is fused to at least two NLSs. In some embodiments, the RNA-guided nuclease is fused to at least three NLSs. In some embodiments, the RNA-guided nuclease is fused to at least one N-terminal NLS and at least one C-terminal NLS. In some embodiments, the RNA-guided nuclease is fused to at least two C-terminal NLSs. In some embodiments, the RNA-guided nuclease is fused to at least two N-terminal NLSs.

[0238] In some embodiments, the NLS is independently selected from SPKKKRKVEAS (SEQ ID NO: 123), GPKKKRKVAAA (SEQ ID NO: 124), PKKKRKV (SEQ ID NO: 125), KRPAATKKAGQAKKKK (SEQ ID NO: 126), PAAKRVKLD (SEQ ID NO: 127), RQRRNELKRSP (SEQ ID NO: 128), NQSSNFGPMKGGNFGGRSSGPYGGGGQYFAKPRNQGGY (SEQ ID NO: 129), RMRIZFKNKGKDTAELRRRRVEVSVELRKAKKDEQILKRRNV (SEQ ID NO: 130), VSRKRPRP (SEQ ID NO: 131), PPKKARED (SEQ ID NO: 132), POPKKKPL (SEQ ID NO: 133), SALIKKKKKMAP (SEQ ID NO: 134), DRLRR (SEQ ID NO: 135), NO:135), PKQKKRK (SEQ ID NO:136), RKLKKKIKKL (SEQ ID NO:137), REKKKFLKRR (SEQ ID NO:138), KRKGDEVDGVDEVAKKKSKK (SEQ ID NO:139), RKCLQAGMNLEARKTKK (SEQ ID NO:140).

[0239] In some embodiments, the RNA-guided nuclease is fused to a heterologous NES. In some embodiments, the RNA-guided nuclease is fused to at least two NESs. In some embodiments, the RNA-guided nuclease is fused to at least three NESs. In some embodiments, the RNA-guided nuclease is fused to at least one N-terminal NES and at least one C-terminal NES. In some embodiments, the RNA-guided nuclease is fused to at least two C-terminal NESs. In some embodiments, the RNA-guided nuclease is fused to at least two N-terminal NESs.

[0240] In some embodiments, the NES is independently selected from an adenovirus type 5 E1B NES, an HIV Rev NES, a MAPK NES, or a PTK2 NES.

[0241] In some embodiments, the RNA-guided nuclease is fused to an NLS and an NES, with a cleavable linker present between the NLS and the NES. In some embodiments, the NES promotes production of delivery particles (e.g., virus-like particles) comprising the RNA-guided nuclease in a production cell line. In some embodiments, cleavage of the linker in a target cell can expose the NLS and promote nuclear localization of the RNA-guided nuclease in the target cell.

[0242] Cas proteins

[0243] In some embodiments of the present disclosure, the Cas protein is Cas9 protein, Cas12 protein or Cas13 protein. In some embodiments, the Cas protein is Cas12a protein, Cas12b protein, Cas12c protein, Cas12d protein, Cas12e protein, Cas12f protein, Cas12g protein, Cas12h protein, Cas12i protein, Cas12j protein, Cas12k protein.

[0244] In some embodiments of the present disclosure, the Cas protein is a Cas13 protein.

[0245] In some embodiments of the present disclosure, the Cas protein is Cas13a protein, Cas13b protein, Cas13c protein or Cas13d protein. In some embodiments of the present disclosure, the Cas protein is a Cas13a protein, Cas13b protein or Cas13c protein in which both HEPN domains carry mutations, and the cleavage activity of these Cas proteins is completely or partially lost. In some embodiments, the Cas protein is a CasRx protein. In some embodiments, the Cas protein is a dCasRx in which both HEPN domains carry mutations (R239A, H244A of HEPN-1 and R858A, H863A of HEPN-2).

[0246] In some embodiments of the present disclosure, the Cas protein comprises the sequence shown in SEQ ID NO:107.

[0247] In some embodiments of the present disclosure, the Cas protein comprises any one or more of the following fusion domains: a subcellular localization signal, a deaminase domain, a translation activation domain, a translation repression domain, an RNA methylation domain, an RNA demethylation domain, a nuclease domain, a splicing factor domain, a reporter tag, and an affinity tag.

[0248] In some embodiments of the present disclosure, the Cas protein comprises a subcellular localization signal.

[0249] In some embodiments of the present disclosure, the Cas protein comprises a subcellular localization signal and a deaminase domain.

[0250] In some embodiments of the present disclosure, the subcellular localization signal is selected from a nuclear localization signal and a nuclear export signal.

[0251] In some embodiments of the present disclosure, the Cas protein is covalently linked to the fusion domain with or without a linker sequence; that is, the Cas protein is directly covalently linked to the fusion domain (without a linker sequence) or covalently linked via a linker sequence. Typically, the linker sequence consists of 1-100, 1-50, 1-30, 1-20, 1-10, or 1-5 amino acids.

[0252] Nucleotide sequence encoding guide RNA or RNA-guided nuclease

[0253] In some embodiments, the nucleotide sequence encoding the RNA-guided nuclease is a plasmid. In some embodiments, the nucleotide sequence encoding the RNA-guided nuclease is part of a viral vector genome, such as the DNA genome of an AAV vector flanked by ITRs. In some embodiments, the nucleotide sequence encoding the RNA-guided nuclease is an mRNA.

[0254] In some embodiments of the present disclosure, the nucleotide sequence encoding the guide RNA or RNA-guided nuclease is codon-optimized.

[0255] In some embodiments of the present disclosure, the nucleotide sequence encoding the guide RNA is DNA. In some embodiments, the sequence of the DNA is codon optimized.

[0256] In some embodiments of the present disclosure, the nucleotide sequence encoding the RNA-guided nuclease is DNA or mRNA. In some embodiments, the sequence of the DNA is codon-optimized. In some embodiments, the sequence of the mRNA is codon-optimized.

[0257] In some embodiments of the present disclosure, codon optimization is performed for expression in a desired cell type. In some embodiments, codon optimization is performed for expression in a eukaryotic cell environment. In some embodiments, codon optimization is performed for expression in a mammalian cell environment. In some embodiments, codon optimization is performed for expression in a human cell environment.

[0258] Codon optimized refers to, by at least one codon (for example, about 1, 2, 3, 4, 5, 10, 15, 20, 25, 50 or more codons) of the original sequence being replaced with a codon that is more frequently used in the gene of this host cell and simultaneously maintaining the original amino acid sequence, modifying the nucleic acid sequence in this way to enhance the expression in the host cell of interest. It is also available to carry out codon optimized computing programs or algorithms, such as can use the following tools or algorithms to carry out codon optimized: ExpOptimizer, Codon OptimWiz, NGTM Codon, Codon optimization, Synthetic Gene Designer and DNAWorks etc.

[0259] recombinant vector

[0260] Recombinant vectors can comprise any type of nucleotides, including but not limited to DNA and RNA, which can be single-stranded or double-stranded, can be partially obtained from natural sources, and can comprise natural, non-natural or altered nucleotides. Suitable vectors include those designed for expression, such as plasmids and viruses.

[0261] In some embodiments, recombinant vectors contain regulatory sequences, such as transcriptional and translational start and stop codons, that are specific for the type of host cell into which the vector is to be introduced (eg, bacteria, fungi, plants, or animals, as appropriate).

[0262] In some embodiments, the recombinant vector optionally includes a gene carrier element (nucleic acid), such as a selectable marker region, a lactose operon, a CMV promoter, a CAG promoter, a tac promoter, a T7 RNA polymerase promoter, an SP6 RNA polymerase promoter, an SV40 promoter, an IRES sequence, a WPRE element, an ITR sequence, a FLAG tag coding region, a c-myc tag coding region, a polyHis tag coding region, an HA tag coding region, an MBP tag coding region, a GST tag coding region, a ployA coding region, an SV40 polyadenylation signal, an SV40 replication origin, a Col E1 replication origin, a loxP site, or a Cre recombinase coding region.

[0263] Regulatory sequences

[0264] In some embodiments of the present disclosure, the regulatory sequence comprises one or more pol III promoters (e.g., 1, 2, 3, 4, 5, or more pol III promoters), one or more pol II promoters (e.g., 1, 2, 3, 4, 5, or more pol II promoters), one or more pol I promoters (e.g., 1, 2, 3, 4, 5, or more pol I promoters), or a combination thereof.

[0265] promoter

[0266] In some embodiments of the present disclosure, the vector comprises a pol III promoter (e.g., U6 and H1 promoters), a pol II promoter (e.g., retroviral Rous sarcoma virus (RSV) LTR promoter (optionally with RSV enhancer), cytomegalovirus (CMV) promoter (optionally with CMV enhancer), SV40 promoter, dihydrofolate reductase promoter, β-actin promoter, phosphoglycerol kinase (PGK) promoter, or EF1α promoter), or a pol III promoter and a pol II promoter.

[0267] In some embodiments of the present disclosure, the promoter is a constitutive promoter, which is continuously active and not regulated by external signals or molecules. Suitable constitutive promoters include, but are not limited to, CMV, RSV, SV40, EF1α, CAG, and β-actin promoters. In some embodiments, the promoter is an inducible promoter regulated by external signals or molecules (e.g., transcription factors).

[0268] In some embodiments of the present disclosure, the promoter is a tissue-specific promoter, which can be used to drive the tissue-specific expression of Cas13 protein. Suitable muscle-specific promoters include but are not limited to CK8, MHCK7, myoglobin promoter (Mb), desmin (Desmin) promoter, muscle creatine kinase promoter (MCK) and variants thereof, and SPc5-12 synthetic promoters. Suitable immune cell-specific promoters include but are not limited to B29 promoter (B cell), CD14 promoter (monocyte), CD43 promoter (leukocyte and platelet), CD68 (macrophage) and SV40 / CD43 promoter (leukocyte and platelet). Suitable blood cell-specific promoters include but are not limited to CD43 promoter (leukocyte and platelet), CD45 promoter (hematopoietic cell), INF-β (hematopoietic cell), WASP promoter (hematopoietic cell), SV40 / CD43 promoter (leukocyte and platelet), and SV40 / CD45 promoter (hematopoietic cell). Suitable pancreas-specific promoters include but are not limited to elastase-1 promoter. Suitable endothelial cell-specific promoters include, but are not limited to, the Fit-1 promoter and the ICAM-2 promoter. Suitable neuronal tissue / cell-specific promoters include, but are not limited to, the GFAP promoter (astroglial cells), the SYN1 promoter (neurons), and the NSE / RU5' promoter (mature neurons). Neuronal tissue / cell-specific promoters can be the GFAP promoter and the SYN1 promoter. Suitable kidney-specific promoters include, but are not limited to, the NphsI promoter (podocytes). Suitable bone-specific promoters include, but are not limited to, the OG-2 promoter (osteoblasts, odontoblasts). Suitable lung-specific promoters include, but are not limited to, the SP-B promoter (lungs). Suitable liver-specific promoters include, but are not limited to, the SV40 / Alb promoter. Suitable heart-specific promoters include, but are not limited to, α-MHC.

[0269] enhancer

[0270] In some embodiments of the present disclosure, the enhancer is selected from the group consisting of WPRE, CMV enhancer, SV40 enhancer, and an intronic sequence between exons 2 and 3 of rabbit β-globin.

[0271] In some embodiments of the present disclosure, the enhancer is located upstream of the promoter element; however, it can also be located downstream or within the coding sequence regulated by the promoter and maintain function. Therefore, the enhancer or a portion thereof can be present in the RNA sequence transcribed from the coding sequence.

[0272] In some embodiments of the present disclosure, the enhancer may be located within 100, 200, 300, 400, 500 or more base pairs upstream or downstream of the coding sequence regulated by the promoter.

[0273] In some embodiments of the disclosure, an enhancer increases expression of a coding sequence above that provided by a promoter.

[0274] Aptamer / aptamer sequence

[0275] In some embodiments, the guide polynucleotide further comprises an aptamer sequence. In some embodiments, the aptamer sequence is inserted into a loop of the guide polynucleotide. In some embodiments, the aptamer sequence is attached to the end of the guide polynucleotide.

[0276] In some embodiments, the aptamer sequence comprises an MS2 aptamer sequence, a PP7 aptamer sequence, or a Qβ aptamer sequence.

[0277] Adaptor protein

[0278] In some embodiments, the gene editing system further comprises a fusion protein comprising an adaptor protein and a fusion domain, or a nucleic acid encoding the fusion protein, wherein the adaptor protein is capable of binding to an aptamer sequence.

[0279] In some embodiments, the linker protein comprises an MS2 phage coat protein (MCP), a PP7 phage coat protein (PCP), or a Qβ phage coat protein (QCP). In some embodiments, the fusion domain comprises a cytosine deaminase domain, an adenosine deaminase domain, a translation activation domain, a translation repression domain, an RNA methylation domain, an RNA demethylation domain, a nuclease domain, a splicing factor domain, or an affinity or reporter tag or domain.

[0280] Adeno-associated virus vector (AAV vector)

[0281] In some embodiments of the present disclosure, the AAV vector comprises a ssDNA genome comprising coding sequences for an RNA-guided nuclease and a guide RNA flanked by ITRs.

[0282] In some embodiments of the present disclosure, the guide RNA or gene editing system described herein is packaged in an AAV vector, such as AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, and AAVrh74. In some embodiments, the gene editing system described herein is packaged in an AAV vector comprising an engineered capsid with tissue tropism, such as an engineered neural tissue tropism capsid.

[0283] lipid nanoparticles

[0284] In some embodiments of the present disclosure, in addition to RNA payload (mRNA and guide RNA encoding the nuclease guided by RNA), lipid nanoparticles (LNPs) also include four components: cations or ionizable lipids, cholesterol, helper lipids, and PEG-lipids. In some embodiments, the cations or ionizable lipids include cKK-E12, C12-200, ALC-0315, DLin-MC3-DMA, DLin-KC2-DMA, FTT5, Moderna SM-102, and Intellia LP01. In some embodiments, the PEG-lipid includes PEG-2000-C-DMG, PEG-2000-DMG, or ALC-0159. In some embodiments, the helper lipid includes DSPC.

[0285] Lentiviral vectors

[0286] In some embodiments of the present disclosure, the lentiviral vector is pseudotyped with a homologous or heterologous envelope protein, such as VSV-G. In some embodiments, the mRNA encoding the RNA-guided nuclease is linked to an aptamer sequence.

[0287] RNP complex (ribonucleoprotein complex)

[0288] In some embodiments of the present disclosure, the RNP complex (ribonucleoprotein complex) can be delivered to eukaryotic cells, mammalian cells or human cells by microinjection or electroporation. In some embodiments, the ribonucleoprotein complex can be packaged in virus-like particles and delivered to mammals or human subjects in vivo.

[0289] virus-like particles

[0290] In some embodiments of the present disclosure, engineered virus-like particles (VLPs) are pseudotyped with homologous or heterologous envelope proteins such as VSV-G. In some embodiments, the RNA-guided nuclease is fused to a gag protein (e.g., MLVgag) via a cleavable linker, wherein the cleavage of the linker in the target cell exposes an NLS between the linker and the RNA-guided nuclease. In some embodiments, the fusion protein comprises (e.g., from 5' to 3') a gag protein (e.g., MLVgag), one or more NESs, a cleavable linker, one or more NLSs, and an RNA-guided nuclease. In some embodiments, the RNA-guided nuclease is fused to a first dimerization domain capable of dimerizing or heterodimerizing with a second dimerization domain fused to a membrane protein, wherein the presence of a ligand promotes the dimerization and enriches the RNA-guided nuclease or fusion protein into the VLP.

[0291] eukaryotic cells

[0292] In some embodiments of the present disclosure, the eukaryotic cell is a mammalian cell or a human cell. In some embodiments, the eukaryotic cell is a primary eukaryotic cell, a stem cell, a tumor / cancer cell, a circulating tumor cell (CTC), a blood cell (for example, a T cell, a B cell, a NK cell, a Tregs cell, etc.), a hematopoietic stem cell, a specialized immune cell (such as a tumor infiltrating lymphocyte or a tumor suppressor lymphocyte), a stromal cell (such as a cancer-associated fibroblast, etc.) in a tumor microenvironment. In some embodiments, the cell is a brain or neuronal cell (for example, a neuron, astrocyte, microglia, retinal ganglion cell, a rod / cone cell, etc.) of a central or peripheral nervous system.

[0293] Diseases or conditions associated with target RNA

[0294] In some embodiments of the present disclosure, the disease or condition associated with the target RNA refers to a disease or condition caused by abnormal expression of the target RNA. In some embodiments of the present disclosure, the disease or condition associated with the target RNA refers to a disease or condition caused by abnormally high expression of the target RNA. In some embodiments of the present disclosure, the disease or condition associated with the target RNA refers to a disease or condition caused by abnormally low expression of the target RNA. In some embodiments of the present disclosure, the disease or condition associated with the target RNA refers to a central nervous system disease or a visual impairment disease. In some embodiments of the present disclosure, the disease or condition associated with the target RNA refers to a central nervous system disease. In some embodiments of the present disclosure, the disease or condition associated with the target RNA refers to a visual impairment disease. In some embodiments of the present disclosure, the disease or condition associated with the target RNA refers to Parkinson's disease. In some embodiments of the present disclosure, the disease or condition associated with the target RNA refers to a retinal disease, such as a retinal disease caused by neurodegeneration, the symptoms of which are mainly manifested as decreased vision and / or blindness.

[0295] In some embodiments of the present disclosure, the target RNA is PTBP1 RNA.

[0296] In some embodiments of the present disclosure, the target RNA is human PTBP1 RNA, mouse PTBP1 RNA, or monkey PTBP1 RNA.

[0297] In some embodiments of the present disclosure, a therapeutically effective amount of the gene editing system or pharmaceutical composition described herein is delivered to a subject in need using a suitable delivery method, which can inhibit the expression or activity of Ptbp1 RNA or its encoded protein in cells in brain tissue and promote the transdifferentiation of brain astrocytes into neurons, thereby diagnosing, preventing and / or treating central nervous system diseases, such as Parkinson's disease, Alzheimer's disease and the like.

[0298] In some embodiments of the present disclosure, a therapeutically effective amount of the gene editing system or pharmaceutical composition described herein is delivered to a subject in need using a suitable delivery method, which can inhibit the expression or activity of Ptbp1 RNA or its encoded protein in Müller glial cells in the retina, and can effectively induce the transdifferentiation of Müller glial cells into retinal ganglion cells, thereby diagnosing, preventing and / or treating neurological diseases related to functional neuronal death.

[0299] In some embodiments, the pharmaceutical composition is delivered to a human subject in vivo. The pharmaceutical composition can be delivered by any effective route, and a therapeutically effective amount of the pharmaceutical composition can be delivered to a subject in need. Exemplary routes of administration include, but are not limited to, intracerebral injection, intraparenchymal injection, cerebral vein injection, intraventricular injection, intracisterna magna injection (ICM) and intrathecal injection, intravenous infusion, intravenous injection, intraperitoneal injection, intramuscular injection, intratumor injection, subcutaneous injection, intradermal injection, intraventricular injection, intravascular injection, intracerebellar injection, intraocular injection, subretinal injection, intravitreal injection, intracameral injection, intratympanic injection, intranasal administration, and inhalation.

[0300] On the basis of conforming to the common sense in this field, the above-mentioned preferred conditions can be arbitrarily combined to obtain the preferred embodiments of the present disclosure.

[0301] The present disclosure is further illustrated by way of examples below, but the present disclosure is not limited to the scope of the examples. Experimental methods in the following examples without specifying specific conditions were performed according to conventional methods and conditions, or selected according to the product specifications.

[0302] Example

[0303] Example 1. Preparation of a gene editing system targeting PTBP1

[0304] 1. Composition of the gene editing system targeting PTBP1

[0305] The gene editing system targeting PTBP1 disclosed herein includes a highly active Cas13 protein, namely C13-2, also known as CasRfg.4 (the amino acid sequence of the C13-2 protein is shown in SEQ ID NO: 107), and a series of gRNAs targeting PTBP1 RNA of humans, mice, and monkeys.

[0306] The mouse Ptbp1 RNA target may be NCBI Reference Sequence NM_001077363.3, whose nucleotide sequence is shown in SEQ ID NO: 121.

[0307] The monkey Ptbp1 RNA target may be NCBI Reference Sequence XM_015122300.2, the nucleotide sequence of which is shown in SEQ ID NO: 122.

[0308] The human Ptbp1 RNA target may be NCBI Reference Sequence NM_002819.5.

[0309] 2. Expression plasmid and construction of gene editing system targeting PTBP1

[0310] 1. Construction of each C13-2-gRNA plasmid

[0311] 1) Artificially synthesized C13-2-BsaI plasmid (C13-2-BsaI plasmid nucleotide sequence is shown in SEQ ID NO: 108), wherein the C13-2-BsaI plasmid contains a codon-optimized C13-2 protein coding sequence (CMV-driven expression) and a direct repeat sequence coding sequence (U6-driven expression).

[0312] The corresponding direct repeat sequence of C13-2 is:

[0313] 5'-GGAAGATAACTCTACAAACCTGTAGGGTTCTGAGAC-3' (SEQ ID NO: 109).

[0314] 2) After annealing the forward and reverse primers corresponding to the gRNA guide sequence, they were ligated with the digested product of the C13-2-BsaⅠ plasmid using T4 ligase to construct each C13-2-gRNA plasmid. The specific steps are as follows:

[0315] The sense and antisense strands of the DNA sequence were synthesized using conventional methods. For the C13-2-BsaI plasmid, the sense strand was constructed by appending agac to the 5'-end of the guide sequence listed in Tables 1-3, and the antisense strand was constructed by appending aaaa to the 5'-end of the reverse complement of the guide sequence. The sense and antisense strands of the DNA sequence were mixed and annealed to form double-stranded DNA with sticky ends (annealed primers).

[0316] The C13-2-BsaⅠ plasmid was linearized using BsaⅠ enzyme digestion, reacted at 37°C for 2 hours, and subjected to 1% agarose gel electrophoresis. The linearized backbone (enzyme digestion product) was recovered by gel excision.

[0317] The annealed primers, enzyme digestion products and DNA Ligation Kit Ver.2.1 (TAKARA, 6022Q) were mixed and incubated in a PCR instrument at 16°C for 1 hour to complete the ligation of the double-stranded DNA with sticky ends to the linearized backbone to obtain the reaction product.

[0318] The reaction products were transformed into competent E. coli Stbl3 cells and cultured in a medium containing the appropriate antibiotics. Positive clones were screened for PCR and plasmids were extracted and verified by Sanger sequencing to obtain the respective C13-2-gRNA plasmids. Each C13-2-gRNA plasmid can be used to express the C13-2 protein and the respective gRNA targeting PTBP1 RNA.

[0319] 2. CasRx-gRNA plasmid construction

[0320] 1) Artificially synthesized CasRx-BpiⅠ plasmid (CasRx-BpiⅠ plasmid nucleotide sequence is shown in SEQ ID NO: 119), wherein the CasRx-BpiⅠ plasmid contains the coding sequence of CasRx (CMV-driven expression) and the coding sequence of the direct repeat sequence (U6-driven expression).

[0321] The direct repeat sequence corresponding to CasRx is: 5'-CAAGTAAACCCCTACCAACTGGTCGGGGTTTGAAAC-3' (SEQ ID NO: 120).

[0322] 2) After annealing the forward and reverse primers corresponding to the gRNA guide sequence, they were ligated with the digestion product of the CasRx-BpiⅠ plasmid using T4 ligase to construct the CasRx-gRNA plasmid. The specific steps are as follows:

[0323] The sense and antisense DNA sequences were synthesized by conventional methods. Using CasRx multiplexing, the sequence GTGGTTGGAGAACTGGATGTAGATGGGCTGcaagtaaacccctaccaactggtcggggtttgaaacAATAAAGAGGCTTTGGGGTGTGACTCTCTC (SEQ ID NO: 118) was used to construct annealing primers. The sense strand was synthesized by adding aaac to the 5' end of the sequence, and the antisense strand was synthesized by adding cttg to the 5' end of the reverse complement of the sequence.

[0324] The annealed primer was ligated with the BpiⅠ linearized product of the CasRx-BpiⅠ plasmid using T4 ligase to construct a CasRx-gRNA plasmid that can express CasRx, 3sg9gRNA, and 3sg10gRNA.

[0325] Table 1. PTBP1 RNA levels after editing in human 293T cells

[0326] Table 2. Levels of edited PTBP1 RNA in mouse N2A cells

[0327] Table 3. PTBP1 RNA levels after editing in monkey COS-1 cells

[0328] Example 2. Detection of editing efficiency

[0329] 1. Transfection

[0330] Strictly following the Life Tech Lipofectamine 2000 (Thermo Fisher) reagent usage procedures, each C13-2-gRNA plasmid was transfected into human HEK293T cells, mouse N2A cells, and monkey COS-1 cells (the negative control group was transfected with the C13-2-BsaI plasmid). The day before transfection, cells in good condition were seeded into 24-well plates at 1×105 / well. On the day of transfection, 500ng of each C13-2-gRNA plasmid was added to 50μl OPTI-MEM (Thermo), and 1μl of LipofacTamine 2000 was added to 50μl OPTI-MEM culture medium. After mixing, the diluted plasmid DNA was mixed with Lipofactamine 2000 and allowed to stand at room temperature for 15min. Then, 100μl of the plasmid DNA complex was added to each well of the 24-well plate and the culture plate was gently shaken to mix. Incubate at 37°C for 72 hours.

[0331] 2. Detection of editing efficiency

[0332] 72 hours after plasmid transfection, total cellular RNA was first extracted using the Ecoray Universal RNA Extraction Kit, and then gDNA was digested and reverse transcribed using the Evo M-MLV Reverse Transcription Kit to obtain the corresponding cDNA. Finally, the obtained cDNA was used as a template for Q-PCR reaction.

[0333] Q-PCR reactions were performed using the SYSB Green Pro Taq HS Premix qPCR Kit, using gapdh as an internal control, to determine PTBP1 RNA levels after cleavage of PTBP1 RNA in each group. Each primer pair was used for each sample in triplicate. Q-PCR primers are listed in Table 4 below.

[0334] Pass 2 -ΔΔCTCalculation Method: Calculate the relative expression level of PTBP1 RNA after knockdown. Subtract this relative value from 1 to obtain the editing efficiency (knockdown efficiency). The knockdown efficiency test results are shown in Tables 1-3.

[0335] The data in the table show that in human 293T cells, 3sg6, H23, H43, and HMK71-HMK73 gRNAs can achieve higher editing efficiencies. Although the target sequences of the gRNAs (same length as the guide sequence) are adjacent to the PTBP1 RNA, surprisingly, the editing efficiency of H43 gRNA is higher than that of H42 and H44 gRNAs (P<0.01); the editing efficiency of HMK72 gRNA is higher than that of H20, H21, HMK71, and HMK73 gRNAs (P<0.01); the editing efficiency of HMK71-HMK73 gRNA is much higher than that of HMK74 gRNA (P<0.01); and the editing efficiency of H23 gRNA is much higher than that of H34, H24, and H25 gRNAs targeting adjacent regions (P<0.01).

[0336] In mouse N2A cells, M55-M57, M59, and M62 gRNAs achieved higher editing efficiency. M55-M57, M59, and M62 gRNAs are located at 638-685 nt of the NCBI NM_001077363.3 sequence (SEQ ID NO: 121).

[0337] In monkey COS-1 cells, HMK71-HMK73 also achieved higher editing efficiency. Surprisingly, as in human cells, HMK72 gRNA had a higher editing efficiency than HMK71 and HMK73 gRNAs (P < 0.01).

[0338] Table 4. Primers used in Q-PCR

[0339] Example 3. RNA sequencing and off-target analysis

[0340] 1. Experimental Methods

[0341] 1. Transfection

[0342] Plasmids were transfected according to the methods of Examples 1 and 2 to complete gene editing of human cell lines (HEK293T) or mouse cell lines (N2A) with C13-2 protein and H20, H21, H23, H34, H42, H43, H44, HMK72 gRNA, and M55 gRNA. A negative control group was transfected with the C13-2-BsaI plasmid. After transfection, the cells were incubated at 37°C for 72 hours. RNA was extracted using a kit.

[0343] Plasmids were transfected using the methods of Examples 1 and 2 to complete gene editing of a human (HEK293T) and mouse (N2A) cell line with CasRx protein and 3sg9 and 3sg10 gRNAs. A negative control group was transfected with the C13-2-BsaI plasmid. After transfection, the cells were incubated at 37°C for 72 hours. RNA was extracted using a kit.

[0344] 2. RNA Sequencing and Off-Target Analysis

[0345] 72 hours after plasmid transfection, total cellular RNA was extracted using the Acridine Universal RNA Extraction Kit. The extracted RNA samples were then sequenced using PE150bp RNA-Seq. The resulting fastq files were aligned with bowtie2 to remove rRNA sequences and then aligned to the target species reference genome using HISAT2 or STAR software to obtain a BAM file. Transcripts and gene expression levels were detected using kallisto, RSEM, or HTSeq. Differential expression levels between groups were analyzed using sleuth or DESeq2. Genes with a corrected p-value qval < 0.05 and a logarithmic expression fold change |b| > = 0.5 were identified as differentially expressed genes (DEGs).

[0346] Differential expression analysis of transcripts is more sensitive and can reflect changes in the expression levels of different transcripts in the same gene. However, the differential expression of individual transcripts in a gene may not necessarily lead to differential expression of the entire gene. Therefore, in the final analysis, the differential expression at the gene level is still used to compare the potential off-target levels of the two experimental groups.

[0347] 2. Experimental Results

[0348] 1. Editing effect at the target gene transcript level

[0349] The average of the top three expressed transcripts from the target gene was taken to calculate the expression and knockdown levels. The results are shown in Table 5 below.

[0350] The results showed that in human HEK293T cells, the knockdown efficiency of the H23gRNA group was better than that of the 3sg9+3sg10 group. In mouse N2A cells, the knockdown efficiency of the M55gRNA group was better than that of the 3sg9+3sg10 group.

[0351] Table 5. PTBP1 RNA knockdown data obtained by RNA sequencing

[0352] 2. Off-target analysis

[0353] The EMBOSS-water program was used to predict the target species (Homo sapiens / Mus musculus) in the whole genome and full cDNA sequence under the conditions of gap_extend=0.5&gap_extend=10. The forward and reverse strands of the gRNA guide sequence were used for alignment, and the prediction results were filtered to obtain the predicted potential target genes (target genes and off-target genes).

[0354] The filtering conditions are as follows:

[0355] The minimum matching length between the gRNA guide sequence and the target sequence is no less than 18 bases;

[0356] The maximum number of mismatches between the gRNA guide sequence and the target sequence does not exceed 6 bases;

[0357] The maximum number of consecutive matching bases between the gRNA guide sequence and the target sequence is no less than 8 bases.

[0358] The intersection of differentially downregulated genes and predicted potential target genes was taken as the target gene with higher credibility. The target gene set excluding the target gene PTBP1 was the off-target gene set. The results are shown in Table 6 below.

[0359] The results showed that in human HEK293T cells, the number of off-target genes in the H23, H43, and HMK72gRNA groups was 0, indicating no off-target risk; while the other experimental groups had multiple off-target genes, so the safety risk of off-target was high.

[0360] In human HEK293T cells, 3sg9+3sg10 gRNA editing showed a high risk of off-target effects. In mouse N2A cells, the M55 gRNA group showed no off-target effects; surprisingly, the 3sg9+3sg10 gRNA group also showed no off-target effects, demonstrating significant differences in 3sg9+3sg10 gRNA editing across species.

[0361] In summary, the editing efficiency of H23, H43, and HMK72 gRNAs combined with C13-2 was high and the off-target risk was low, thus achieving unexpected technical effects.

[0362] Table 6. Calculated predicted potential target genes and the targeted and off-target genes obtained by intersection

[0363] Example 4. C13-2 mutant targets PTBP1 RNA

[0364] The C13-2 protein mutant vectors shown in Table 7 were constructed using conventional methods and, following the methods of the previous examples, combined with H30 gRNA for editing in monkey COS1 cells and human 293T cells. qPCR results showed that the editing efficiency of the C13-2 protein, M2-18 variant, M2-25 variant, and M2-33 variant combined with H30 gRNA was greater than 35%.

[0365] Table 7. Mutants of C13-2

[0366] Off-target detection was performed using the same method as in the previous example, and the results are shown in Figures 4 and 5. This indicates that under the set threshold conditions, in 293T cells, there was no off-target effect after combined editing of the M2-25 mutant and the H30 gRNA, and there was no off-target effect after combined editing of the C13-2 protein and the H30 gRNA.

[0367] Example 5. Verification of transdifferentiation by detecting markers in a Parkinson's disease monkey model experiment

[0368] Using stereotaxic brain injection, an adeno-associated virus (AAV) vector containing the expression cassettes for the M2-25 mutant of C13-2 and the H30 gRNA was injected into the substantia nigra of Parkinson's disease monkeys (on the left side of the brain; the right side served as a negative control, with an AAV vector expressing only the M2-25 mutant of C13-2 and no H30 gRNA). The goal was to edit the target PTBP1 RNA in astrocytes and reduce PTBP1 RNA expression. After a period of time, the substantia nigra region was extracted for single-cell sequencing and qPCR analysis, which revealed upregulation of DCX-1, a marker for astrocyte-to-neuronal transdifferentiation, an increase in intermediate neuroblasts, and downregulation of GFAP-2 and S100B, markers of astrocytes. This is shown in Figures 6 and 7.

[0369] Specifically, we used scRNA-Seq to capture the reprogramming trajectory mediated by the C13-2-M2-25+H30 gRNA drug. We injected PD mice with AAV virus, sorted C13-2-M2-25-positive cells, and performed scRNA sequencing. Two samples were prepared: an AAV vector expressing the C13-2-M2-25+H30 gRNA drug and AAV-ctrl. We then performed batch correction, clustering, and dimensionality reduction to generate a map of all analyzed cells (Figure 7A). In this map, each cell cluster, represented by the same color, indicates that these cells share transcriptome-wide similarities and therefore may represent different cell states, cell types, or subtypes. We then used a panel of known marker genes to identify a broad range of cell types. To focus on cells most relevant to drug-mediated reprogramming, we selected neural clusters enriched for C13-2-M2-25-positive cells (Figure 7C) and demonstrated Ptbp1 expression within these clusters (Figure 7D). By calculating diffusion pseudotime and then sorting cells based on pseudotime, we found that early-stage cells were dependent on C13-2-M2-25 expression. Among these cells, more neuroblasts and neurons were found after drug treatment, indicating an increase in the number of intermediate cells with the ability to reprogram and differentiate into neurons. Overall, the C13-2-M2-25+H30gRNA drug promoted cell type changes, particularly an increase in midbrain neuroblasts and neurons, indicating the occurrence of transdifferentiation.

[0370] Example 6. C13-2-gRNA editing improves the disease phenotype of Parkinson's disease model mice

[0371] Using stereotactic brain injection, an adeno-associated virus (AAV) vector containing the expression cassette of the M2-25 mutant of C13-2 and the M55gRNA expression cassette was injected into the substantia nigra of Parkinson's disease model mice. Tests were performed after a period of time. Compared to the negative control group (injected with an AAV vector expressing only the M2-25 mutant of C13-2 and not the M55gRNA), the appropriate dose of AAV therapeutic drug inhibited apomorphine-induced rotations, increased the time the mice spent on the rotarod, and generally improved the behavioral dysfunction of the mice. This is shown in Figure 8.

Claims

1. A gRNA, which is any one of the following 1)-3): 1) the gRNA comprises a targeting domain, wherein the targeting domain comprises a sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 98% or 100% identity with the sequence shown in SEQ ID No: 122; 2) the gRNA comprises a targeting domain, the targeting domain comprising a sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 98% or 100% identity with the sequence shown in positions 638-685 of SEQ ID No: 121; 3) The gRNA includes a targeting domain, which comprises a sequence shown in any one of SEQ ID No: 1 to SEQ ID No: 8 or SEQ ID No: 11 to SEQ ID No: 60, or a sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 98% or 100% identical to the sequence shown in any one of SEQ ID No: 1 to SEQ ID No: 8 or SEQ ID No: 11 to SEQ ID No:

60.

2. The gRNA according to claim 1, characterized in that: In the above 1), the gRNA includes a targeting domain, which comprises a sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 98% or 100% identical to the sequence shown in positions 627-3697 of SEQ ID No:

122.

3. The gRNA according to claim 1 or 2, characterized in that: In the above 1), the gRNA includes a targeting domain, which comprises a sequence shown in any one of SEQ ID No: 85 to SEQ ID No: 105 or a sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 98% or 100% identity with any one of SEQ ID No: 85 to SEQ ID No:

105.

4. The gRNA according to any one of claims 1 to 3, characterized in that: In the above 2), the gRNA includes a targeting domain, which comprises a sequence shown in any one of SEQ ID No: 61 to SEQ ID No: 84 or a sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 98% or 100% identity with any one of SEQ ID No: 61 to SEQ ID No:

84.

5. The gRNA according to any one of claims 1 to 4, characterized in that: In the above 3), the gRNA includes a targeting domain, which comprises a sequence as shown in any one of SEQ ID No:6, SEQ ID No:16, SEQ ID No:36, SEQ ID No:40, SEQ ID No:41, and SEQ ID No:42, or a sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 98% or 100% identical to any one of SEQ ID No:6, SEQ ID No:16, SEQ ID No:36, SEQ ID No:40, SEQ ID No:41, and SEQ ID No:

42.

6. The gRNA according to any one of claims 1 to 5, characterized in that: The gRNA includes a targeting domain, and the targeting domain comprises a sequence shown in any one of SEQ ID No: 1 to SEQ ID No: 38, SEQ ID No: 40 to SEQ ID No: 51, SEQ ID No: 53 to SEQ ID No: 57, SEQ ID No: 59 to SEQ ID No: 88, SEQ ID No: 90, SEQ ID No: 91, SEQ ID No: 95 to SEQ ID No: 105 or a sequence with any one of SEQ ID No: 1 to SEQ ID No: 38, SEQ ID No: 40 to SEQ ID No: 51, SEQ ID No: 53 to SEQ ID No: 57, SEQ ID No: 59 to SEQ ID No: 88, SEQ ID No: 90, SEQ ID No: 91, SEQ ID No: 95 to SEQ ID Any of the sequences shown in No:105 has a sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 98% or 100% identical.

7. The gRNA according to any one of claims 1 to 6, characterized in that: The gRNA includes a targeting domain, and the targeting domain comprises a sequence shown in any one of SEQ ID No: 1 to SEQ ID No: 3, SEQ ID No: 6, SEQ ID No: 9 to SEQ ID No: 12, SEQ ID No: 16, SEQ ID No: 18 to SEQ ID No: 21, SEQ ID No: 23, SEQ ID No: 24, SEQ ID No: 28, SEQ ID No: 30, SEQ ID No: 34, SEQ ID No: 36, SEQ ID No: 40 to SEQ ID No: 42, SEQ ID No: 51, SEQ ID No: 55, SEQ ID No: 61 to SEQ ID No: 76, SEQ ID No: 80 to SEQ ID No: 82, SEQ ID No: 84, SEQ ID No: 98, and SEQ ID No: 104, or a sequence shown in any one of SEQ ID No: 1 to SEQ ID No: 3, SEQ ID No: 6, SEQ ID No: 9 to SEQ ID No: 12, SEQ ID No: 16, SEQ ID No: 18 to SEQ ID No: 21, SEQ ID No: 23, SEQ ID No: 24, SEQ ID No: 28, No:23, SEQ ID No:24, SEQ ID No:28, SEQ ID No:30, SEQ ID No:34, SEQ ID No:36, SEQ ID No:40 to SEQ ID No:42, SEQ ID No:51, SEQ ID No:55, SEQ ID No:61 to SEQ ID No:76, SEQ ID No:80 to SEQ ID No:82, SEQ ID No:84, SEQ ID No:98, and SEQ ID No:104, a sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 98% or 100% identity.

8. The gRNA according to any one of claims 1 to 7, characterized in that: The gRNA includes a targeting domain, which comprises a sequence shown in any one of SEQ ID No:61 to SEQ ID No:76, SEQ ID No:80 to SEQ ID No:82, and SEQ ID No:84, or a sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 98% or 100% identical to any one of SEQ ID No:61 to SEQ ID No:76, SEQ ID No:80 to SEQ ID No:82, and SEQ ID No:

84.

9. The gRNA according to any one of claims 1 to 8, characterized in that: The gRNA includes a targeting domain, which comprises a sequence shown in any one of SEQ ID No: 98 and SEQ ID No: 104, or a sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 98% or 100% identity with the sequence shown in any one of SEQ ID No: 98 and SEQ ID No:

104.

10. The gRNA according to any one of claims 1 to 9, characterized in that: The gRNA is capable of forming a complex with the RNA-guided nuclease and directing the complex to bind sequence-specifically to the target RNA.

11. The gRNA according to any one of claims 1 to 10, characterized in that: The gRNA is capable of forming a complex with the RNA-guided nuclease and directing the complex to bind to and cleave the target RNA.

12. The gRNA according to claim 10 or 11, characterized in that: The complex reduces the expression level of the target RNA in the animal or animal cell.

13. The gRNA according to any one of claims 10 to 12, characterized in that: The complex reduces the expression level of the target RNA in the animal or animal cell by at least 5%.

14. The gRNA according to any one of claims 10 to 13, characterized in that: The number of off-target genes when the complex binds to and cleaves the target RNA is less than 40.

15. The gRNA according to claim 14, characterized in that: The number of off-target genes is determined by taking the intersection of the differentially expressed gene set determined by RNA sequencing and the off-target gene set predicted by the program.

16. The gRNA according to any one of claims 10 to 15, characterized in that: The RNA-guided nuclease is a Cas protein.

17. The gRNA according to claim 16, characterized in that: The Cas protein is Cas9 protein, Cas12 protein or Cas13 protein.

18. The gRNA according to claim 17, characterized in that: The Cas13 protein is Cas13a protein, Cas13b protein, Cas13c protein or Cas13d protein.

19. The gRNA according to claim 16, characterized in that: The amino acid sequence of the Cas protein is shown in SEQ ID No:

107.

20. The gRNA according to any one of claims 10 to 19, characterized in that: The RNA-guided nuclease further comprises one or more of a subcellular localization signal, a deaminase domain, a translation activation domain, a translation repression domain, an RNA methylation domain, an RNA demethylation domain, a nuclease domain, a splicing factor domain, a reporter tag, and an affinity tag.

21. The gRNA of claim 20, wherein: The subcellular localization signal is a nuclear localization signal or a nuclear export signal.

22. The gRNA according to any one of claims 1 to 21, characterized in that: The size of the gRNA is 20-40bp.

23. The gRNA according to any one of claims 1 to 22, characterized in that: The gRNA hybridizes to the target RNA with a mismatch of no more than 6 nucleotides.

24. The gRNA according to any one of claims 1 to 23, characterized in that: The gRNA also comprises a direct repeat sequence.

25. The gRNA of claim 24, wherein: The gRNA is located at the 3' end or 5' end of the direct repeat sequence.

26. The gRNA of claim 24 or 25, wherein: The directly repeating sequence comprises the sequence shown in SEQ ID No:

109.

27. The gRNA according to any one of claims 1 to 26, characterized in that: The gRNA also comprises an aptamer sequence.

28. The gRNA of claim 27, wherein: The aptamer sequence is located in the loop of the direct repeat sequence secondary structure of the gRNA.

29. The gRNA according to any one of claims 1 to 28, characterized in that: The gRNA also comprises modified nucleotides.

30. The gRNA of claim 29, wherein: The modification method is 2'-O-methyl modification, 2'-O-methyl-3'-phosphorothioate modification or 2'-O-methyl-3'-thio PACE modification.

31. The gRNA of claim 29 or 30, wherein: The modified nucleotide is a deoxyribonucleotide or a locked nucleic acid.

32. The gRNA according to any one of claims 1 to 31, characterized in that: The target RNA is located in the nucleus or cytoplasm of a eukaryotic cell.

33. A DNA sequence encoding the gRNA of any one of claims 1-32.

34. An expression cassette, recombinant vector, recombinant bacteria, recombinant virus or transgenic cell line containing the DNA sequence of claim 33.

35. The recombinant vector according to claim 34, characterized in that: The recombinant vector is a recombinant adeno-associated virus vector or a recombinant lentivirus vector.

36. The recombinant vector according to claim 34 or 35, characterized in that: The recombinant vector also includes a regulatory sequence for regulating the expression of the gRNA.

37. The recombinant vector according to claim 36, characterized in that: The regulatory sequence is a promoter or an enhancer.

38. The recombinant vector according to claim 37, characterized in that: The promoter is a neuron tissue-specific promoter or a neuron cell-specific promoter.

39. A gene editing system comprising (a) and (b): (a) the gRNA according to any one of claims 1 to 32, or a DNA sequence encoding the gRNA, or an expression cassette, a recombinant vector, a recombinant bacterium, a recombinant virus, or a transgenic cell line containing a DNA sequence encoding the gRNA; (b) the RNA-guided nuclease of any one of claims 16 to 21, or a DNA sequence encoding the RNA-guided nuclease, or an expression cassette, a recombinant vector, a recombinant bacterium, a recombinant virus, or a transgenic cell line containing a DNA sequence encoding the RNA-guided nuclease; The gRNA is capable of forming a complex with the RNA-guided nuclease and directing the sequence-specific binding of the complex to the target RNA. Combine.

40. The gene editing system of claim 39, wherein: The gRNA is capable of forming a complex with the RNA-guided nuclease and directing the complex to bind to and cleave the target RNA.

41. The biological material related to the gene editing system of claim 39 or 40 is any one of the following X1)-X7): X1) A vector system comprising the gene editing system of claim 39 or 40, comprising a DNA sequence encoding the gRNA and a first regulatory sequence regulating the expression of the gRNA; and a DNA sequence encoding the RNA-guided nuclease and a second regulatory sequence regulating the expression of the RNA-guided nuclease; X2) an adeno-associated virus vector comprising the gene editing system of claim 39 or 40, comprising a DNA sequence encoding the RNA-guided nuclease and the gRNA; X3) A lipid nanoparticle comprising the gene editing system of claim 39 or 40, comprising the gRNA and an mRNA encoding the RNA-guided nuclease; X4) A lentiviral vector comprising the gene editing system of claim 39 or 40, comprising the gRNA and an mRNA encoding the RNA-guided nuclease; X5) A ribonucleoprotein complex comprising the gene editing system of claim 39 or 40, which is formed by the gRNA and the nuclease guided by the RNA; X6) A virus-like particle comprising the gene editing system of claim 39 or 40, comprising a ribonucleoprotein complex formed by the gRNA and the nuclease guided by the RNA; X7) A eukaryotic cell comprising the gene editing system of claim 39 or 40.

42. The biomaterial according to claim 41, characterized in that: In the X1), the regulatory sequence is a promoter or an enhancer.

43. The biomaterial according to claim 41, characterized in that: In the X4), the lentiviral vector is obtained by pseudotyping with envelope protein.

44. The biomaterial according to claim 41, characterized in that: In the X4), the mRNA encoding the RNA-guided nuclease is linked to the aptamer sequence.

45. The biomaterial according to claim 41, characterized in that: In said X6), said RNA-guided nuclease is fused to the gag protein.

46. ​​A pharmaceutical composition comprising the gRNA of any one of claims 1-32, the DNA sequence of claim 33, the expression cassette, recombinant vector, recombinant bacteria, recombinant virus or transgenic cell line of any one of claims 34-38, the gene editing system of claim 39 or 40, or the biological material of any one of claims 41-45, and pharmaceutically acceptable excipients.

47. Use of the gRNA of any one of claims 1-32, or the DNA sequence of claim 33, or the expression cassette, recombinant vector, recombinant bacterium, recombinant virus or transgenic cell line of any one of claims 34-38, or the gene editing system of claim 39 or 40, or the biomaterial of any one of claims 41-45, or the pharmaceutical composition of claim 46 in any one of the following Y1)-Y8): Y1) cleaving one or more target RNA molecules or causing nicks in one or more target RNA molecules; Y2) activating or upregulating one or more target RNA molecules; Y3) inhibiting, down-regulating or inactivating one or more target RNA molecules; Y4) visualizing, labeling or detecting one or more target RNA molecules; Y5) binding to one or more target RNA molecules; Y6) transporting one or more target RNA molecules; Y7) masking one or more target RNA molecules; Y8) Prepare a drug for diagnosing, treating or preventing a disease or condition associated with the target RNA.

48. The use according to claim 47, characterized in that: The target RNA is PTBP1 RNA.

49. The use according to claim 47 or 48, characterized in that: The target RNA is human PTBP1 RNA, mouse PTBP1 RNA or monkey PTBP1 RNA.

50. The use according to any one of claims 47 to 49, characterized in that: The disease or disorder associated with the target RNA is a disease or disorder caused by abnormal expression of the target RNA.

51. A method for diagnosing, treating or preventing a disease or condition associated with a target RNA, comprising the following steps: administering the gRNA of any one of claims 1-32 or the DNA sequence of claim 33 or the expression cassette, recombinant vector, recombinant bacteria, recombinant virus or transgenic cell line of any one of claims 34-38 or the gene editing system of claim 39 or 40 or the biological material of any one of claims 41-45 or the pharmaceutical composition of claim 46 to a sample of a subject in need or to a subject in need.

52. The method of claim 51, wherein: The target RNA is PTBP1 RNA.

53. The method according to claim 51 or 52, characterized in that: The target RNA is human PTBP1 RNA, mouse PTBP1 RNA or monkey PTBP1 RNA.

54. The method according to any one of claims 51 to 53, characterized in that: The disease or disorder associated with the target RNA is a disease or disorder caused by abnormal expression of the target RNA.

Citation Information

Patent Citations

  • Application of Ptbp1 inhibitor in preventing and / or treating nervous system diseases related to functional neuronal death

    CN112386699A

  • SgRNA and application thereof

    CN112522271A

  • Crispr-CAS systems having destabilization domain

    US20210222164A1

  • Compositions and methods for treatment of neurological diseases

    WO2023245670A1

  • Gene editing system and use thereof

    WO2024088175A1